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Abstract 
This study proposes to directly test the hypothesis that antibody-dependent 
enhancement (ADE) is the critical factor in the development of dengue 
hemorrhagic fever (DHF) in infants. DHF occurs in two distinct clinical settings: a) 
in children and adults with secondary DENV infection, and b) in infants with 
primary DENV infection born to mothers with prior DENV infection. The ADE 
hypothesis proposes that pre-existing serotype-cross-reactive non-neutralizing 
anti-DENV antibodies bind the heterotypic DENV during secondary infection and 
enhance its uptake into immune cells, leading to increased viral load and DHF. 
This model suggests that DHF in DENV-infected infants is caused by the 
enhancing effect of waning maternal anti-DENV antibodies, thus causing a 
“physiologic secondary infection” during an infant’s primary infection and thereby 
increasing the infant’s risk for DHF.   
 
The effect of maternal immunity on DHF in infants has been studied exclusively 
in Southeast Asia. However, the maternal DENV seroprevalence approaches 
100% in this part of the world. As a consequence, the ADE model of infant DHF 
cannot truly be tested in Southeast Asia, because all infants possess anti-DENV 
antibody at birth. In the Western Hemisphere, by contrast, women may have 
experienced either a single DENV infection, more than one DENV infection, or no 
DENV infection at all. The ability to include DENV-seronegative mothers as 
controls allows for the ADE hypothesis to be directly tested in a clinical study. To 
our knowledge, no such study has been previously conducted. 
This thesis presents a case-control study designed to evaluate the influence of 
positive maternal dengue seroprevalence on the risk of DHF in infants. As the 
MSCI program provides instruction in study design, this thesis does not present 
findings. The clinical trial described herein began in May 2010 and enrollment is 
expected to continue through May 2012 (see Table 4). 
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Introduction 
Overview and Specific Aims 
This study proposes to directly test the hypothesis that antibody-dependent enhancement (ADE) 
is the critical factor in the development of dengue hemorrhagic fever (DHF) in infants. DHF is 
the life-threatening syndrome associated with dengue virus (DENV) infection. DENV infection 
among humans has expanded rapidly over the past 50 years. The increasing incidence makes 
an accurate model of DHF pathogenesis imperative for vaccine development, clinical 
management and public health strategies. 
 
DHF occurs in two distinct clinical settings: a) in children and adults with secondary DENV 
infection, and b) in infants with primary DENV infection born to mothers with prior DENV 
infection. One of the principal models for the pathogenesis of DHF in these two seemingly 
disparate groups is ADE. The ADE hypothesis proposes that pre-existing serotype-cross-
reactive non-neutralizing anti-DENV antibodies bind the heterotypic DENV during secondary 
infection and enhance its uptake into immune cells, leading to increased viral load and DHF. 
This model suggests that DHF in DENV-infected infants is caused by the enhancing effect of 
waning maternal anti-DENV antibodies, thus causing a “physiologic secondary infection” during 
an infant’s primary infection and thereby increasing the infant’s risk for DHF.   
 
The effect of maternal immunity on DHF in infants has been studied exclusively in Southeast 
Asia. However, the maternal DENV seroprevalence approaches 100% in this part of the world. 
As a consequence, the ADE model of infant DHF cannot truly be tested in Southeast Asia, 
because all infants possess anti-DENV antibody at birth. In the Western Hemisphere, by 
contrast, women may have experienced either a single DENV infection, more than one DENV 
infection, or no DENV infection at all. The ability to include DENV-seronegative mothers as 
controls allows for the ADE hypothesis to be directly tested in a clinical study. To our 
knowledge, no such study has been previously conducted. 
 
In brief, the major objectives of my proposed research are: 
#1: Compare rates of dengue seroprevalence of mothers from two groups of infants: 
infants with DHF and those with symptomatic DENV infection but without DHF. The null 
hypothesis of this study is that the proportion of dengue-seropositive mothers of infants with 
DHF infants is equal to the proportion of dengue-seropositive mothers of infants with 
symptomatic DF who do not meet criteria for DHF. To test this, we will compare the rates of 
prior DENV infection in mothers of these two groups of children. Serologic testing for both anti-
dengue IgM and IgG of all serotypes will be performed on all participants using ELISA assays. 
Serum PRNT50 assays—the plaque-reduction neutralization assay and the gold standard test in 
serologic analysis of flavivirus infections—will also be performed. 
 
#2: Test ADE in vitro using the serum from the mothers of both groups of DENV-infected 
infants (as a surrogate for ADE activity of pre-illness infant sera). Antibody-dependent 
enhancement assays are performed by using serial dilutions of serum, followed by incubation of 
DENV-serum mixtures to FcγIIa receptor-bearing K562 or BHK-21 cells at a fixed multiplicity of 
infection, with subsequent measurement of DENV levels by either qRT-PCR, plaque titration, or 
flow cytometry. We propose to measure the ADE activity of a maternal serum dilution that 
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estimates infant dengue antibody levels at the age of infection, comparing mothers of DHF 
infants versus mothers of “not-DHF infants.” 
 
#3: Evaluate the relationship between ADE activity and estimated peak viremia levels. 
The ADE model predicts that increased viral uptake into macrophages directly leads to higher 
viral loads; consequently, there should be a positive correlation between ADE activity and the 
peak viral load. We will perform PCR analysis on all infants with dengue, estimate the peak 
viremia level based on day of illness, and compare these data to ADE activity. 
 
Research Plan 
Background and Significance 
DENV infection is the most common mosquito-borne viral infection in the world today, and has 
been an increasing public health menace over the past few decades. Currently there are an 
estimated 100-150 million annual infections, with an annual mortality of >20,000, the 
overwhelming majority of deaths being in infants and children (1). DENV is a member of the 
flavivirus family, with four distinct but closely related serotypes: DENV-1, DENV-2, DENV-3, and 
DENV-4. Transmitted to humans primarily by Aedes aegypti mosquitoes, DENV is found mostly 
in tropical and subtropical areas worldwide. Classical dengue fever (DF) presents as an acute 
febrile illness characterized by headache, retro-orbital pain, and myalgias. A small group of 
patients go on to develop the manifestations of DHF, which is distinguished from DF principally 
by a vascular leakage phenomenon, leading to hemoconcentration, pleural or peritoneal 
effusions, and, in the most severe cases, dengue shock syndrome (DSS). While death is a 
relatively rare complication, the sheer volume of infections worldwide makes DENV the most 
lethal hemorrhagic fever virus by far—the total number of deaths worldwide from Ebola since 
1976 is just over 1,000; DENV claims an equal number in less than a month. 
 
The protective immune response against DENV remains poorly understood. There are no good 
animal models of human dengue disease (2); therefore, clinical and epidemiologic studies are 
necessary to answer questions relating to DENV pathophysiology. Further, although many 
successful viral vaccines were developed with a minimal understanding of basic viral and 
cellular processes, the development of an effective DENV vaccine requires a more 
comprehensive model of DENV pathophysiology (3). In particular, an understanding of which 
individuals are at risk for developing DHF is a priority in the coming decade. 
 
Epidemic DHF and DSS emerged in the Philippines and Thailand only 50 years ago. Since 
then, the virus has become hyperendemic (i.e., endemic transmission of multiple serotypes)  in 
Southeast Asia, where today it is among the top ten causes of pediatric hospitalization (4). By 
contrast, DENV infection in the Western Hemisphere remained relatively low until the 1970s, 
when DF incidence began to rise, followed by epidemics of DHF and DSS in the 1980’s. Today, 
countries such as Brazil, Venezuela and Colombia are subject to epidemics in increasingly rapid 
succession. The seroprevalence in the West remains less than 100% based on ongoing studies, 
although hyperendemic circulation is becoming established in some areas (5). 
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Immunity and pathogenesis in DENV infection 
One of the unique features of dengue is the role of heterologous infection in disease severity. 
Following infection with a given DENV serotype, an individual will develop long-lasting immunity 
to that serotype (homotypic immunity). However, heterotypic immunity to the remaining three 
serotypes lasts only a few months (6). One key observation in dengue pathogenesis is that 
heterotypic immunity is a risk factor for DHF: the overwhelming majority of DHF cases occur in 
people who are experiencing secondary infections with a different DENV serotype (7). The 
major exception to this group is in infants, where “primary DHF” is most commonly seen during 
the period from 6-12 months.  
 
One widely accepted theory to account for the occurrence of DHF in these different groups is 
ADE (8) (9, 10). The ADE model proposes that pre-existing heterotypic anti-DENV IgG 
antibodies (Abs) acquired during a previous infection can, under certain conditions, facilitate 
uptake of virus into macrophages (purportedly the main target cell for DENV) and possibly other 
immune cells via the binding of virus-antibody complexes to Fcγ receptors. The consequent 
increase in receptor-mediated endocytosis of non-neutralized virus particles causes something 
resembling a “Trojan Horse” phenomenon, leading to higher viral loads, which in turn triggers a 
host inflammatory cascade that leads to DHF. 
 
The sine qua non of the ADE hypothesis is its prediction of a primary-infection DHF 
phenomenon in infants, where maternally derived anti-DENV IgG levels decay over time. Infant 
immune systems are “primed” in utero by passive transfer of DENV-specific Abs from DENV-
immune mothers, thus creating a “physiologic secondary infection” during primary DENV 
infection, where waning maternal anti-DENV Abs enhance viral uptake, resulting in DHF. Figure 
1 illustrates a schematic showing the risk of DHF based on the ADE hypothesis. 
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Figure 1. ADE hypothesis in an infant model. Waning maternal DENV Ab levels are 
initially able to neutralize all four DENV serotypes. However, as anti-DENV Ab 
levels decline (between approximately 4-6 months), the infant enters a “window 
phase” where DENV-specific Abs paradoxically facilitate intact virus uptake into 
immune cells, leading to abnormally high viral loads and increased risk for DHF. 
Following this “window” period, Ab levels are sufficiently low that they have no 
effect on subsequent infection, and infants exposed to DENV during this period are 
at risk of DF but have substantially reduced risk, or no risk, of DHF.  
 
Several epidemiologic studies have shown that the incidence of primary DHF in infants peaks 
approximately between 6 and 8 months of age (11). This time frame corresponds with predicted 
ADE activity, and in vitro studies have borne this out. Kliks et al were able to demonstrate a 
correlation between mothers neutralizing titers (to DENV-2) and infant age at the time of onset 
of DHF and Dengue Shock Syndrome (12), while Chau et al noted a strong temporal 
association between the enhancing activity of plasma and the age of the infant in a cohort of 
Vietnamese children (13). However, other studies have cast doubt on the ADE hypothesis: 
Laoprasopwattana et al were unable to demonstrate any correlation between the enhancing 
activity of DENV in K562 cells and the clinical severity or viral burden of Thai schoolchildren 
experiencing secondary DENV-2 or DENV-3 infection (14); Libraty et al evaluated a cohort of 
Filipino infants experiencing primary infection (largely DENV-3) and were unable to find 
significant differences in DENV-3 ADE between infants with DHF and those with less severe 
symptomatic disease  (15). Reflecting these contradictory findings, one investigator recently 
noted that because measurements of ADE rely on in vitro models, its association with clinical 
outcomes remains controversial (16), stating that “to the best of our knowledge, DHF has not 
yet been described in an infant born to a dengue-naïve mother…further studies of infants with 
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DHF, particularly in regions with low or moderate dengue endemicity or where outbreaks occur 
among previously naïve populations, are needed to unequivocally confirm that maternally 
derived anti-DENV antibody is a critical risk factor for DHF in infants.”  
 
South America as a location to study the effect of maternal Ab on infant DHF 
We have identified a promising site to study the influence of maternal dengue serostatus on the 
severity of infant DENV infection. Our collaborators are faculty members in the Department of 
Pediatrics, Universidad Surcolombiana (USCO) Hospital. We are currently working with them on 
a project evaluating a novel assay for the detection of dengue viremia. A city of approximately 
300,000 people, Neiva is an ideal site for studying dengue in infants for two major reasons: it is 
a large enough city to have a sufficient number of cases of severe DENV infection, but it is small 
enough only to support one pediatric hospital allowing for a “funneling” of cases of severe 
dengue. USCO is not only the sole inpatient pediatric hospital for the city but for the surrounding 
region (Estado Huila). Thus, our collaborators and their department care for essentially all cases 
of pediatric DHF in Neiva.  
 
One of the critical elements in a study to evaluate the effect of maternal antibody in primary 
DHF in infants is to have an adequate number of both seropositive and seronegative mothers, 
as well as a sufficient number of cases of infant DHF. That is, if the overall DENV 
seroprevalence in a study site is too low, then the likelihood of obtaining an adequate number of 
cases of infant DHF is likewise low; conversely, the higher the endemicity, the more difficult it is 
to find seronegative mothers. An ideal study would include not only seronegative mothers, but 
“monotypic” mothers (i.e. having been infected with only one serotype) and “multitypic” ones 
(those with a history of infections from at least two separate serotypes—current testing cannot 
distinguish between patients infected with two, three or all four serotypes). 
 
In order to estimate the maternal DENV seroprevalence, we obtained sera from a cohort of 121 
pregnant women who had been enrolled in a study in 2006 evaluating the protective effects of 
pre-natal pneumococcal vaccination on infants. The initial results of the anti-DENV IgG ELISA 
testing can be seen in Figure 2. Overall, the estimated seroprevalence based on these findings 
is approximately 32% (39 of 121). We assume this seroprevalence to be artificially low due to 
the fact that an estimated 20% of the women in this study came from the surrounding 
mountains, which support a climate too cool for the survival of Aedes aegypti and thus the 
transmission of dengue (personal communication). This would theoretically increase the overall 
seroprevalence among women living in the region at risk for dengue to roughly 40% as of 2006. 
The dengue seroprevalence likely has increased in the intervening years based on 
epidemiologic trends noted throughout northern South America over the past decade, though 
doubtfully to levels that would preclude the possibility of seronegative mothers. We have 
recently been shipped the samples and are performing PRNT50 tests to evaluate the percentage 
of mothers with monotypic or multitypic infection. 
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Table 1 shows the number of estimated number of cases of suspected DHF requiring 
hospitalization in Neiva in 2007 distributed by age. The number of cases in children <1yr of age 
in Neiva in 2007 was 94. A substantially higher number of DF cases were seen in infants who 
did not require hospitalization (personal communication), so the minimum sample size should 
be easily met (see “Study Design” below). 
 
 
Table 1: 2007 cases of suspected DHF, by age group 
(n=639, laboratory-confirmed in 472) 
Age (in years) # Males # Females 
<1 66 28 
1-4 75 90 
5-14 99 102 
15-44 80 55 
45-64 10 12 
>65 10 11 
 
Study Design 
We will conduct a case-control study comparing infants and mothers of the following groups: 
those with DHF and those with symptomatic DENV infection but without DHF. For appropriate 
categorization during the analysis phase, all infants will require positive laboratory evidence of 
acute DENV infection (serology or PCR). Infants with DHF will be defined according to the 
World Health Organization criteria, which include all of the following: thrombocytopenia, a 
bleeding tendency, and plasma leakage. 
 
Infants brought by their mothers seeking medical care, and identified by clinical staff as having 
suspected symptomatic DENV infection, will be screened either in the inpatient or emergency 
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ward at USCO. Plasma leakage in DHF occurs in the period immediately following 
defervescence. Therefore, children in the symptomatic DENV cohort will be monitored clinically 
until after they have been documented to be free of any DHF manifestations 24 hours after 
defervescence in order to ensure appropriate categorization (see “Categorization of infants into 
DF versus DHF arms” under Laboratory and Study Procedures” below for further information). 
 
At the initial visit clinical information on both the infant and the mother will be collected, and 
blood will be drawn from both the mother and infant. Mothers of infants at the outpatient clinic 
will be given information about warning signs of severe DENV disease and instructed to return 
to the clinic immediately if the infant develops such symptoms. Hospitalized infants with DHF 
will be cared for according to standard clinical procedures in place at USCO. To ensure that 
infants initially categorized in the non-DHF arm do not subsequently develop DHF, the study will 
involve two visits, the second focusing entirely on the infant’s clinical progression, occurring 
between 48 and 72 hours after the initial visit. Furthermore, the second visit allows for a second 
blood draw in order to perform the study tests required for accurate diagnosis of acute DENV 
infection. At the second visit, infants in the outpatient clinic will be re-examined and have blood 
drawn. Infants at the second visit with ongoing fever will be re-evaluated in a third visit 24-72 
hours later, but no further blood will be drawn except as required for standard clinical care. 
Infants with DHF will be re-evaluated at the second visit, and relevant clinical information (chest 
X-rays, hematocrit and platelet values, amount of IV fluid administered) will be recorded and 
additional blood will be drawn. Mothers will have their blood drawn at the first visit only. Figure 3 
shows the timeline of visits and the main objectives of each visit. 
 
Visit #1: 
- Confirm suitability for study
- Maternal History questionnaire
- Infant History questionnaire
- Mother blood draw
- Infant blood draw
Visit #2: 
- Infant chart review & data 
extraction
- Determine DHF vs. DF status
- Infant blood draw
Day 0 Day 2-3
Figure 3. Study Visits
Day 4-6
Visit #3: 
-Clinical evaluation 
(only in infants with 
fever at visit #2)
- Chart review & data 
extraction
- No blood draw
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Patient Recruitment 
Inclusion criteria include: 
•Infants aged 12 months or less and their healthy mothers; these infants belong to two groups: 
•Those hospitalized for suspected DHF*; and 
•Those sick from suspected infection with dengue but who do not meet the criteria for DHF*;  
•Active pregnancy in the mother does not affect inclusion or exclusion criteria. 
*Identification of potential study subjects are initially based on clinician suspicion of dengue 
infection in the case of an acute febrile illness, and are accompanied by laboratory findings of 
leukopenia, thrombocytopenia, and/or elevated transaminases.  
 
Exclusion criteria include: 
•For mothers: any febrile illness since the time of delivery of the infant (to exclude an intervening 
DENV infection); 
•Inability or unwillingness to provide informed consent 
•HIV infection. 
 
•For infants: any use of IVIG prior to study inclusion; 
•HIV infection. 
 
Clinical and demographic data will be collected on the mothers, including age, past or current 
medical history (including specifically a history of Yellow Fever vaccination, previous known 
dengue infection, previous hemorrhagic fever, diabetes, lupus or other autoimmune diseases, 
asthma, TB and HIV), and medications. Similar information will be collected on the infants; 
additionally, information on the length of illness, time from symptom onset to presentation, 
specific treatments or interventions used, serial CBCs and CXRs, serial blood pressure 
measurements, presence or absence of complications, serial weight and height measurements, 
and mortality will also be collected.  
 
Laboratory and Study Procedures 
Mothers will have 12 ml of blood collected at the first visit only; infants will have no more than 
the amount defined as minimal risk (see Appendix #3), as measured by infant weight, on two 
consecutive blood draws between 48 and 72 hours apart.  
 
Serologic testing for both anti-dengue IgM and IgG of all serotypes will be performed on both 
mothers and infants using ELISA. The maternal IgM will be performed to evaluate for recent 
acute DENV infection, which could lead to misclassification of infant/mother pairs. To further 
delineate between DENV-naïve, monotypic and multitypic serostatus, serum plaque-reduction 
neutralization (PRNT50) assays (17) will also be performed on maternal sera. Due to a 
nationwide vaccination campaign in 2006 in Colombia for the related flavivirus Yellow Fever, 
ELISA assays for IgG antibodies to Yellow Fever virus will also be utilized, consistent with 
standard dengue antibody research protocols. 
 
In infants, serum NS1 assays, which have a higher sensitivity during acute infection than ELISA 
IgM, will also be used. Acute DENV infection in infants will be defined as either a positive anti-
DENV IgM, a positive NS1 ELISA, or a positive DENV PCR test. Neutralizing antibody titers will 
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be interpreted as described in the literature (18). Along with the PRNT50 assays, antibody-
dependent enhancement assays will be performed following techniques described in the 
literature (14).  
 
Table 2: Laboratory tests to be run on Mothers and Infants 
Mothers Infants 
DENV IgM ELISA DENV IgM ELISA 
DENV IgG ELISA DENV IgG ELISA 
PRNT50  DENV PCR 
YF IgG ELISA DENV NS1 ELISA 
 
 
Categorization of infants into DF versus DHF arms. The WHO criteria for establishing DHF 
requires the presence of the following four components: fever; hemorrhagic manifestations, 
as defined either by a positive tourniquet test, the presence of skin bleeding (either petechiae or 
ecchymoses), or mucosal bleeding (either epistaxis, menorrhagia, or GI bleeding); 
thrombocytopenia (platelets <100,000 cells/ml); and evidence of plasma leakage in the form 
of pleural effusion, ascites, hypoproteinemia, or hemoconcentration to levels ≥20% baseline 
values). To ensure all infants included in the DHF arm meet the criteria, a separate Case Report 
Form will be used documenting that the infant has met the DHF criteria (see Appendix #1). 
 
Data will be recorded on paper case report forms (CRFs; see Appendix 1), which will be kept at 
USCO. Copies will be transferred to UMass electronically, on a periodic basis for data analysis. 
The data will be retained on a password protected network drive at UMass. 
 
No specific interventions will occur as part of the study. All medical therapy, including the use of 
oral or intravenous fluid supplementation, will be administered at the discretion of the attending 
physician and will follow standard medical care. 
 
Study Objectives 
Objective #1: Compare rates of dengue seroprevalence of mothers from two groups of 
infants: infants with DHF and those with symptomatic DENV infection but without DHF. 
To test the main hypothesis, we will determine whether the DENV seroprevalence is 
significantly higher in mothers of infants with DHF than in mothers of infants without DHF. 
Based upon estimated seroprevalences of 100% among mothers of infants with DHF and 80% 
among mothers of infants without DHF, with α of .05 and β of .2, we calculate that the minimal 
sample size requirement would be 36 in each arm.  
 
The 80% estimate of maternal seroprevalence in the non-DHF arm is highly conservative, with a 
considerably higher DENV seroprevalence than the 32% seroprevalence observed in the cohort 
from the maternal pneumococcal vaccination study (Fig. 2). We have used the 80% figure to 
ensure that the sample size is not an underestimate, and to account for potential discrepancies 
between current maternal DENV seroprevalence and that found in the cohort from 
pneumococcal immunization study, including but not limited to the participation of likely 
seronegative mothers living in surrounding mountainous regions (who are not expected to be 
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enrolled in our current study at the same rate, if at all), as well as the increase in seroprevalence 
in the years since the pneumococcal vaccination study. Since the ADE hypothesis requires the 
presence of declining maternal antibodies as a prerequisite for infant DHF, the seroprevalence 
in the DHF arm is, by definition, 100 percent. 
 
We propose to recruit in a 1:2 case-control fashion, with a minimum of 50 mother/infant pairs in 
the DHF group and 100 mother/infant pairs in the symptomatic DENV group, allowing for 
withdrawals and loss to follow-up. Statistical analysis for the main study objective will be 
performed using Fisher’s exact test to detect differences in proportions.  
 
Objective #2: Test ADE in vitro using the serum from the mothers of both groups of 
DENV-infected infants (as a surrogate for ADE activity of pre-illness infant sera). Since 
the ADE hypothesis predicts that infants who develop DHF should have a higher degree of ADE 
activity than infants who develop symptomatic DF but not DHF, we plan to evaluate the 
enhancing activity of sera as part of this study. The recent study by Libraty et al (15), which was 
prospective in nature, allowed for the collection of pre-illness plasma samples from infants and 
therefore direct testing of enhancement activity from infant samples; this will not be possible in 
this case-control study. Consequently, maternal sera, diluted in order to estimate infant dengue 
antibody levels at the age of infection, will be used as a surrogate and tested for enhancing 
activity by ADE assays as described in the literature (14, 15, 19, 20). We will use the Student’s 
t-test for comparisons of mean values between normally distributed continuous variables 
(assuming normality). 
 
Objective #3: Evaluate the relationship between ADE activity and estimated peak viremia 
levels. The ADE model also predicts that infants with DHF have higher viral loads than those 
with DF but not DHF, and it has been demonstrated that higher viral loads are associated with 
DHF (21, 22). We plan to compare ADE activity and the level of viremia in both groups of 
infants. While we cannot know with certainty, based on the non-prospective design of this study, 
the peak viremia level during an infant’s illness, we will use viremia levels within 3 days after 
illness onset as an estimate for peak viremia, consistent with previous studies. If we are unable 
to obtain infant sera within this time course, we plan to compare viremia levels between infants 
in both arms categorized by days after onset of illness. Pearson correlation test will be used to 
measure correlation between ADE activity and estimated peak viral load (assuming normality). 
Stata™ software will be used for all statistical analysis. 
 
Future Directions & Speculative Areas 
One of the potentially unique aspects of this study is the possibility that there will be a 
serologically heterogenous cohort of mothers, not merely in terms of the binary division of 
seronegative versus seropositive, but also in that we may be able to identify mothers with 
monotypic infection. Thus, we can study the influence of maternal antibodies to a particular 
serotype on subsequent infant infection, e.g. a mother with a PRNT50 indicating a history of 
DENV-2 infection paired with an infant experiencing DENV-3 infection. Based on the overall 
sample size, the expected low frequency of monotypic immune mothers, the tendency for one or 
two DENV serotypes to predominate in any given year, and the fact that the number of possible 
sequential orders of infection is 12, we do not expect to enroll an adequate sample size for all 
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potential comparisons. Nevertheless, such serologic groups have never before been described 
to the best of our knowledge. 
 
Additionally, we intend to evaluate the influence of serotype on disease severity. The circulating 
strains in Neiva are not currently known, but given the estimated time for patient recruitment 
(approximately 12-20 months), we would expect to have mostly or entirely one circulating 
serotype. While other studies have compared infants infected with predominantly one serotype 
(12, 15), this may be the first study to do so with a serologically heterogenous group, allowing 
for meaningful sub-group analysis. 
 
Patient Protections 
All procedures involving patient recruitment (including the use of Spanish-language consent 
forms), as well as use of Protected Health Information is being done with approval of the 
Institutional Review Boards of UMass and USCO. The UMass IRB application (docket #13644, 
approved 2/2/10), can be found in Appendix #2. As part of ongoing studies, all investigators and 
relevant personnel at UMass and USCO have taken the CITI Responsible Conduct of Research 
Course. 
 
Proposed Timeline 
Figure 4 illustrates the proposed timeline. Patient recruitment began in May 2010 and is 
expected to last approximately 15 months. Formal data analysis will begin in early 2011 and is 
expected to take approximately one year’s time. Manuscript(s) will be prepared following the 
completion of all data analysis. 
 
May 2010
Begin patient 
recruitment 
Patient Recruitment Period
Figure 4. Study Timeline
September 2011
End patient 
recruitment
Data Analysis Period
May 2012
Study completion
1o objectives analyzed
Manuscripts prepared
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Información de los infantes 
Criterios para DHF 
(Versión: 26/03/2010) 
Estudio de las Mamas y Infantes  26 de marzo de 2010 Pagina 1 de 2 
 
SECCIÓN A: INFORMACIÓN GENERAL 
A1 Número de identificación (coloque la 
etiqueta) 
 
A2 Fecha de la admisión (dd/mm/aaaa) __ __ / __ __ / __ __ __ __ 
A3 Fecha del inclusión en el estudio __ __ / __ __ / __ __ __ __ 
A4 Iniciales de la persona que completa la 
forma 
__ __ __ __ 
   
SECCIÓN B: CRITERIOS DE DIAGNOSIS DE 
DENGUE HEMORRAGICO (CRITERIA FOR 
DIAGNOSIS OF DHF [DATA ABSTRACTED FROM 
HOSPITAL CHART]) 
  
B1 Sospecha de infección de dengue? 
(Suspicion for dengue infection?) 
No   Sí  
B2 Trombocitopenia (<100,000)? 
(Thrombocytopenia.) 
No   Sí  
B3 Hemorragia 
(Hemorrhage? If so, where?) 
Ausente   Presente  
Sitio: 
________________________ 
B4 Presión arterial (ahora) 
(Current BP.) 
Sistólica- __ __ __ mm Hg 
Diastólica- __ __ __ mm Hg 
B5 Presión arterial (mínimum) 
(Lowest BP.) 
Sistólica- __ __ __ mm Hg 
Diastólica- __ __ __ mm Hg 
B6 Prueba de torniquete hecho 
(Was a tourniquet test done?) 
No    Si  
B7 Brazo de la prueba 
(Which arm was the test done, L or R?) 
Derecho   Izquierdo  
B8 Resultado cualitativo según el médico 
(Qualitative result according to MD) 
Negativo   Positivo  
B9 Cantidad de las petequias en el patrón 
(Si la cantidad está mas que 20, marque ‘21’.) 
(Amount of petechiae in area; if >20, mark 
__ __ 
__ __ __ - __ __ __ 
                                                           14
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__ __ __ - __ __ __ 
‘21’.) 
B10 Hematócrito (mínimum) 
(Minimum hematocrit.) 
__ __ __ __ 
B11 Hematócrito (máximum) 
(Maximum hematocrit.) 
__ __ __ __ 
B12 Presencia del derrame pleural 
(Presence of pleural effusion.) 
Ausente   Presente  
B13 Presencia de ascitis 
(Presence of ascites.) 
Ausente   Presente  
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SECCIÓN A: INFORMACIÓN GENERAL 
A1 Número de identificación 
(coloque la etiqueta) 
 
A2 Fecha de la visita 
(dd/mm/aaaa) 
__ __ / __ __ / __ __ __ __ 
A3 Fecha de la admisión 
(dd/mm/aaaa) 
__ __ / __ __ / __ __ __ __ 
A4 Iniciales de la persona que 
completa la forma 
__ __ __ __ 
A5 Localización Hospital   Clínica  
   
SECCIÓN B: CRITERIOS DE INCLUSIÓN (INCLUSION CRITERIA) 
B1 Edad <12 meses 
(Age <12 months) 
No   Sí  
B2 ¿Temperatura ≥ 38.5°C o 
fiebre subjetiva en las últimas 
5 días? 
(Temp >38.5 or subjective 
fever in the past 5 days?) 
No   Sí  
B3 Fecha inicio de fiebre 
(dd/mm/aaaa) 
(Date of fever onset.) 
__ __ / __ __ / __ __ __ __ 
B4 ¿Uno o más de los síntomas 
característicos (dolor retro-
ocular o cefalea, mialgias, y 
erupción maculopapular)? 
(One or more of the following 
characteristic symptoms: retro-
orbital pain or headache, 
myalgias, and maculopapular 
rash?) 
No   Sí  
B5 ¿Uno o más de los signos de 
alarma: disminución brusca de 
la temperatura (hipotermia), 
dolor abdominal intenso, 
sangrado en encías/nariz/piel o 
otros sitios? 
No   Sí  
__ __ __ - __ __ __ 
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__ __ __ - __ __ __ 
(One or more of the following 
‘alarm signs’: hypothermia, 
intense abdominal pain, 
bleeding in gums, nose, skin, 
or other sites?) 
   
SECCIÓN C. CRITERIOS DE EXCLUSIÓN (EXCLUSION CRITERIA) 
C1 Edad >12 meses 
(Age >12 months) 
No   Sí  
C2 Uso de inmunoglobulina G en 
el neonato 
(Use of immunoglobulin G as 
a neonate?) 
No   Sí  
   
SECCIÓN D: DATOS DEMOGRÁFICOS (DEMOGRAPHIC DATA) 
D1 Edad (meses y semanas) 
(Age, months & weeks.) 
__ __meses  __ __semanas 
D2 Fecha de nacimiento 
(dd/mm/aaaa) 
(Date of birth.) 
__ __ / __ __ / __ __ __ __ 
D3 Sexo (Sex, M/F.) Masculino   Feminino  
   
SECCIÓN E: FACTORES DE RIESGO (RISK FACTORS) 
E1 Presencia de floreros 
(Presence of 
planters/flowerpots.) 
No   Sí  
E2 Presencia de matas 
sembradas en agua 
(Presence of bushes growing 
in wáter basins.) 
No   Sí  
E3 Presencia de recipientes al 
aire libre 
(Presence of open-air 
containers.) 
No   Sí  
E4 Criaderos en la casa o en los 
vecinos 
(Breeding areas in the house 
or vicinity.) 
No   Sí  
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__ __ __ - __ __ __ 
E5 Presencia de mosquitos en el 
área 
(Presence of mosquitos in the 
area?) 
No   Sí  
E6 Uso de tambores, pipas, o 
pipotes en la casa 
(Use of various types of 
wáter-holding containers in 
the house?) 
No   Sí  
E7 Suministro de agua en forma 
continua 
(Running wáter?) 
No   Sí  
E8 Almacena el agua en la casa 
(Water storage in the house?) 
No   Sí  
E9 Disponibilidad de recolección 
de basura (Availability of 
garbage collection?) 
No   Sí  
E10 Hay neumáticos o cauchos 
en la casa (Are there tires or 
other rubber tubes in the 
house?) 
No   Sí  
E11 Uso de tela metálica en 
ventanas (Are there screens 
in the windows?) 
No   Sí  
E12 Uso de insecticidas en la 
casa (Are insecticides used in 
the house?) 
No   Sí  
E13 Uso de repelente (Are insect 
repellents used?) 
No   Sí  
E14 Cerca a su casa hay 
llanterías, carros 
abandonados, pozos, 
construcciones 
(Are there wells, abandoned 
cars, or construction areas 
near the house?) 
No   Sí  
   
   
SECCIÓN F: SINTOMAS DE LA ENFERMEDAD (SYMPTOMS OF 
ILLNESS) 
F1 Malestar general (Malaise) Ausente   Presente  
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__ __ __ - __ __ __ 
F2 Astenia (Asthenia) Ausente   Presente  
F3 Fatiga (Fatigue) Ausente   Presente  
F4 Cansancio (Sleepiness) Ausente   Presente  
F5 Irritabilidad (Irritability) Ausente   Presente  
F6 Anorexia (Weight loss) Ausente   Presente  
F7 Nauseas (Nausea) Ausente   Presente  
F8 Vómitos ocasionales 
(Occasional vomiting) 
Ausente   Presente  
F9 Vómitos persistentes 
(Persistent vomiting) 
Ausente   Presente  
F10 Diarrea (Diarrhea) Ausente   Presente  
F11 Tos (Cough) Ausente   Presente  
F12 Rinorrea (Runny nose) Ausente   Presente  
F13 Disnea (Shortness of breath) Ausente   Presente  
F14 Diaforesis (Sweats) Ausente   Presente  
F15 Escalofríos (Chills) Ausente   Presente  
F16 Erupción (Rash) Ausente   Presente  
F17 Hematomas (Bruises) Ausente   Presente  
F18 Epistaxis (Nosebleed) Ausente   Presente  
F19 Hemoptisis (Hemoptysis) Ausente   Presente  
F20 Hematemesis Ausente   Presente  
F21 Melena Ausente   Presente  
F22 Hematuria Ausente   Presente  
   
SECCIÓN G: HISTORIA MÉDICA (MEDICAL HISTORY) 
G2 Amamantando (Nursing?) Ausente   Presente  
G3 Hemofilia (Hemophilia?) Ausente   Presente  
G4 Otro tipo de hemorragia 
(Other hemorrhagic 
condition?) 
Ausente   Presente  
G6 SIDA (AIDS?) Ausente   Presente  
G8 Asma (Asthma?) Ausente   Presente  
G9 Diabetes mellitus Ausente   Presente  
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__ __ __ - __ __ __ 
SECCIÓN H: USO DE MEDICAMENTOS DURANTE LA ENFERMEDAD 
H1 Acetaminofen No   Sí  
H2 Aspirina No   Sí  
H3 Anti-inflamatorio no esteroide 
(NSAIDS) 
No   Sí  
H4 Corticoesteroides 
(Corticosteroids) 
No   Sí  
H8 Otros 
(Other; if so, specify.) 
No   Sí  
Especificar: ___________________ 
   
SECCIÓN I: EXPOSICIÓN A FLAVIVIRUSD 
I3 Otros casos de dengue en la 
familia en los últimos 14 días 
(Other cases of dengue in the 
family in the past 14 days?) 
No   Sí  
   
SECCIÓN J: HISTORIA DE VIAJES (TRAVEL HISTORY) 
J1 Ha viajado en los últimos 14 días 
(Has the infant traveled in the past 14 
days? If so, where?) 
No   Sí  
Dónde: ___________________ 
   
SECCIÓN K: EXÁMEN FÍSICO (PHYSICAL EXAM) 
K1 Temperatura oral (Temp, oral) __ __ , __ °C 
K2 Talla (Height) __ , __ __ M 
K3 Peso (Weight) __ __ __ , __ kg 
K4 Frecuencia cardiaca (Heart rate, BPM) __ __ __ latidos/minuto 
K5 Presión arterial (Blood pressure) Sistólica- __ __ __ mm Hg 
Diastólica- __ __ __ mm Hg 
K6 Frecuencia respiratoria (Respiratory rate) _______ respiraciones/minuto 
K7 Letárgia (Lethargy) Ausente   Presente  
K8 Ictericia (Icterus) Ausente   Presente  
K9 Erupción (Rash) Ausente   Presente  
K10 Petequias (Petechiae) Ausente   Presente  
K11 Hematomas/equimosis (Hematomas or Ausente   Presente  
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__ __ __ - __ __ __ 
ecchymoses) 
K12 Hemorragia (Frank hemorrhage; if so, 
where) 
Ausente   Presente  
Sitio: ________________________ 
K13 Derrame pleural (Pleural effusion) Ausente   Presente  
K14 Dolor abdominal a la palpación 
(Abdominal pain on palpation) 
Ausente   Presente  
K15 Ascitis (Ascites) Ausente   Presente  
K16 Hepatomegalia (Hepatomegaly)  Ausente   Presente  
K17 Esplenomegalia (Splenomegaly) Ausente   Presente  
K18 Edema Ausente   Presente  
   
SECCIÓN L: PRUEBA DE TORNIQUETE (TOURNIQUET TEST) 
L1 Prueba de torniquete hecho 
(Has a tourniquet test been done?) 
No    Si  
L2 Brazo de la prueba 
(On which arm was the test done?) 
Derecho   Izquierdo  
L3 Resultado cualitativo según el médico 
(Qualitative results according to MD?) 
Negativo   Positivo  
L4 Cantidad de las petequias en el patrón 
(Si la cantidad está mas que 20, marque 
‘21’.) (Amount of petechiae in area; if >20, 
mark ’21’.) 
__ __ 
   
SECCIÓN M: TOMA DE MUESTRA (BLOOD SAMPLE DRAW) 
M1 Hora de la toma (Time of draw) __ __ __ __ h 
M2 Identificación de la muestra (coloque el 
etiqueta) (Place ID number tag here.) 
 
   
SECCIÓN N: DISPOSICIÓN DEL PACIENTE (PATIENT DISPOSITION) 
N1 Disposición del paciente (Disposition of 
the infant: outpatient, hospitalized, 
referred, place where pt was referred) 
Ambulatorio  
Hospitalizado  
Remitido  
Lugar a donde fue remitido: 
_______________________________ 
__ __ __ - __ __ __ __ 
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__ __ __ - __ __ __ 
   
DATOS DEL REGISTRO EN LA BASE DE DATOS (DATA FOR REGISTRY IN 
DATABASE) 
(Solo para completar por personal admistrativo del estudio) 
(To be completed only by study personnel) 
 
Fecha del registro (dd/mm/aaaa): __ __ / __ __ / __ __ __ __ (Date of registration) 
Iniciales de la persona que ingresa los datos: __ __ __ __ (Initials of person entering data) 
Fecha de la verificación de los datos ingresados (dd/mm/aaaa): __ __ / __ __ / __ __ __ __ 
Iniciales de la persona que verifíca los datos: __ __ __ __ 
(Date of verification of data entry & initials) 
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SECCIÓN A: INFORMACIÓN GENERAL (GENERAL INFORMATION) 
A1 Número de identificación 
(coloque la etiqueta) 
(ID tag #)  
A2 Fecha de la visita (date of 
visit) (dd/mm/aaaa) 
__ __ / __ __ / __ __ __ __ 
A3 Iniciales de la persona que 
completa la forma 
__ __ __ __(initials of person 
completing form) 
   
SECCIÓN B: CRITERIOS DE INCLUSIÓN (INCLUSION CRITERIA) 
B1 ¿Firma de la hoja de 
consentimiento? 
No   Sí  
 (Did the person provide signed consent?)  
SECCIÓN C. CRITERIOS DE EXCLUSIÓN (EXCLUSION CRITERIA) 
C1 ¿Temperatura ≥ 38.5°C o 
fiebre subjetiva desde el 
nacimiento del bebé? 
No   Sí  
 (Temp >38.5 or subjective fever since the 
birth of the baby.) 
 
SECCIÓN D: DATOS DEMOGRÁFICOS (DEMOGRAPHIC DATA) 
D1 Edad (años) Age, years __ __ 
D2 Fecha de nacimiento del 
bebé (dd/mm/aaaa) (Date of 
birth of infant) 
__ __ / __ __ / __ __ __ __ 
D3 Zona de residencia (código) 
(Residential Zone) 
__ __ __ 
   
SECCIÓN G: HISTORIA MÉDICA (MEDICAL HISTORY) 
G1 Antecedentes de dengue 
(History of dengue infection; if 
yes, what year) 
No   Sí  
¿Cuándo? (año)_________________ 
G2 ¿Enfermedad febril durante 
en embarazo? (Did you have 
a febrile illness during your 
No   Sí  
__ __ __ - __ __ __ 
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__ __ __ - __ __ __ 
pregnancy?) 
G3 ¿Vacunación previa fiebre 
amarilla? (Have you been 
vaccinated against Yellow 
Fever? If yes, what year?) 
No   Sí  
¿Cuándo? (año)_________________ 
G4 SIDA (Does the mother have 
AIDS?) 
Ausente   Presente  
G5 Otros casos de dengue en la 
familia en los últimos 14 días 
(Are there other cases of 
dengue in the family in the 
past 14 days?) 
No   Sí  
   
SECCIÓN J: HISTORIA DE VIAJES (TRAVEL HISTORY) 
J1 Ha viajado en los últimos 14 días (Have 
you traveled in the past 14 days? If yes, 
where?) 
No   Sí  
Dónde: ___________________ 
   
SECCIÓN M: TOMA DE MUESTRA (BLOOD SAMPLE DRAWING) 
M1 Hora de la toma (Time of draw) __ __ __ __ h 
M2 Identificación de la muestra (coloque el 
etiqueta) (Place ID tag number here.)  
 
   
SECCIÓN N: DISPOSICIÓN DEL PACIENTE (PATIENT DISPOSITION) 
N1 Disposición del bebé (Disposition of the 
infant: outpatient, hospitalized, referred, 
place where pt was referred) 
Ambulatorio  
Hospitalizado  
Remitido  
Lugar a donde fue remitido: 
_______________________________ 
   
DATOS DEL REGISTRO EN LA BASE DE DATOS (DATA FOR REGISTRY IN 
DATABASE) 
(Solo para completar por personal admistrativo del estudio) 
(To be completed only by study personnel) 
 
__ __ __ - __ __ __ __ 
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__ __ __ - __ __ __ 
Fecha del registro (dd/mm/aaaa): __ __ / __ __ / __ __ __ __ (Date of registration) 
Iniciales de la persona que ingresa los datos: __ __ __ __ (Initials of person entering data) 
 
 
Fecha de la verificación de los datos ingresados (dd/mm/aaaa): __ __ / __ __ / __ __ __ __ 
Iniciales de la persona que verifíca los datos: __ __ __ __ 
 
(Date of verification of data entry & initials) 
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APPLICATION FOR APPROVAL OF UMMS HUMAN STUDIES  
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 
 
NOTICE TO INVESTIGATOR 
 
THE PRINCIPAL INVESTIGATOR IS RESPONSIBLE FOR THE CONTENT OF THIS APPLICATION 
AND MUST
 
 PROOF READ THE FINAL VERSION OF THE APPLICATION FORM BEFORE IT IS 
SUBMITTED.  Errors in the application reflect poorly on the PI’s oversight of the research.  FAILURE TO 
ADEQUATELY REVIEW THE APPLICATION WILL PUT THE STUDY AT HIGH RISK OF BEING 
TABLED UNTIL THE NEXT MEETING. 
Before the IRB meeting deadline, you must submit ONE COPY of the completed IRB application, 
including all 7 of the sections.  All signatures and attachments MUST be in place.  The application and 
consent form must be numbered.  This packet will be pre-reviewed in the Human Subjects Office and 
returned to you.  Copies should not
 
 be made until the pre-review is completed. 
This administrative review is done to prevent receiving applications that are poorly prepared and 
unacceptable to the Committee.  You are urged to prepare this application and consent form carefully.   
The two Human Subjects Committees review 10-20 protocols a month.  The Committees are composed 
of individuals who donate a considerable amount of their time to this effort, and your careful attention to 
accurate, complete information and grammar are fully anticipated.  The Human Subjects staff and the IRB 
reviewers will return the submission to you if this is not the case, resulting in an unnecessary delay in 
study review and your anticipated study initiation 
INSTRUCTIONS 
 
RADIATION OR DNA/CELL LINES 
 
If the subjects receive any radiation, please contact the Radiation Safety Committee (RSC) at 508-856-
3208 to discuss the possibility of RSC review. If RSC review is needed, IRB approval will not be given 
until RSC approval has been obtained. 
 
If the subjects receive any rDNA vaccines, retroviruses, adenovirus derivative vectors, or autologous 
modified tissue, please contact the Institutional Biosafety Committee (IBC) at 508-856-5416 to discuss the 
possibility of IBC review and registration.  If laboratory personnel will be involved with rDNA vaccines, 
retroviruses, adenovirus derivative vectors, or autologous modified tissue this must also be registered with 
the IBC.  If review is needed, IRB approval will not be given until IBC approval has been obtained.  
 
SIGNATURES 
   
1. The PI signs Section III and Section VII the Informational Drug Data Form (IDDF). 
2. The Chair and the Chief of the PI’s Department/Division sign Section IV.  
3.  Additional signatures may also be required in section IV, please review. 
3.  All Research Personnel, including the PI, sign Section VI. 
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PROCEDURES FOR SUBMITTING A COMPLETED APPLICATION  
 
If you are unsure about the type of review required by your study, or are inexperienced in completing IRB 
applications, it is strongly recommended that you provide a copy of a reasonably complete draft version.  
A substantive preliminary review by the Human Subjects Office will be performed.   This preliminary 
review gives you the opportunity to address issues before the meeting and will save you time in the long 
run.  Obviously, this review must be done well in advance of the IRB meeting deadline. 
 
EXPEDITED REVIEW 
If the study qualifies for Expedited Review (determined by the Human Subjects Office after review) the 
original and three copies of the final version of the application will be required.  Two Committee members 
will review the protocol.  This process usually takes approximately three weeks. 
 
FULL COMMITTEE REVIEW 
If the full Committee must review the study, the original and twenty copies will be needed (one for each 
member of the Committee).  Please note that the original copy of the full application and consent 
form must be sent to the Human Subjects Office for initial administrative review before the 
Principal Investigator makes twenty copies for the Committee.    
 
Meetings are scheduled for the first and third Tuesday of each month at 4:00 P.M. (except for the months 
of July and August when the Committee meets once each month).   Meeting dates and deadline dates are 
available on our web page and are subject to change.   
 
Each protocol is reviewed by two committee members prior to the meeting, and the investigator may be 
contacted to respond to concerns.  You will be notified of the date and location of the meeting.  Most 
Principal Investigators do not have to attend the meeting, but you are asked to be on call via your pager 
or telephone between the meeting hours of 4-6 p.m. 
 
AMENDMENTS 
The Human Subjects Office or the IRB must review any amendment or change in a protocol or consent 
form.  No changes may be instituted until the investigator has received written approval of the revision 
from the Committee. 
 
YEARLY REVIEW AND REAPPROVAL 
Approved studies must receive re-approval at least once a year and more often if required by the 
Committee.  A notice will be sent to you before the re-approval is due; approximately 2 months prior to the 
expiration date.  Re-approval must occur within 30 days of the expiration date and appropriate planning 
must take place to meet this required deadline.   
 
Please contact the Human Subjects Office at 856-4261 if you need additional information. 
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     CONTENTS OF THIS APPLICATION 
 
 
 
 
  
 I PRINCIPAL INVESTIGATORS CHECK LIST 
 
 II PROTOCOL SUMMARY SHEET 
 
 III PRINCIPAL INVESTIGATORS ASSURANCE 
 
 IV DEPARTMENTAL APPROVAL 
 
 V DESCRIPTION OF RESEARCH PROJECT 
 
 VI CERTIFICATION OF APPROVAL 
 
 VII INFORMATIONAL DRUG DATA FORM 
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      SECTION I 
 
Before this application is submitted to the Research Subjects Office, the following must be done.   
P ease indicate by stating “YES” OR “N/A” (not applicable) that you have reviewed the packet and 
have accomplished these tasks as they apply to your study. 
 
IN THE APPLICATION SECTION 
 
            Completed Protocol Summary Sheet Section II 
  
           Completed & obtained signatures on the P.I.’s Assurance Section III and  
           Obtained signed agreement forms from all cooperating faculty Section V and departments Section VII. 
  
           Obtained approval from Radiation Safety Committee or submitted protocol to the RSC 
           
           Provided the Investigational New Drug (IND #) on the Protocol Summary Sheet Section II 
  
           If the study is grant funded and you need additional information contact the Research Funding Office at 508-856-2119 .  If the study is 
industry supported, please contact the Office of Clinical Research at 508-856-5015 
  
           Provided 1 copy of the Sponsor Protocol or the “body” of the research grant (e.g. sections a through e of the  
 Research Plan of an NIH grant).  HUMAN SUBJECTS USE MUST BE IDENTICAL IN GRANT/COMPANY PROTOCOL 
  AND IRB APPLICATION. 
  
           Provided 1 copy of the Investigator’s Drug Brochure 
  
           Numbered the pages of the Protocol body. 
  
 Obtained approval from the Institutional Biosafety Committee (IBC) or submitted the protocol to the IBC Committee for review. 
 IN THE CONSENT FORM 
  
           Indicated that subjects will sign a written consent form. 
  
           Provided a consent form in standard UMMS format  
  
           Wrote the consent form in the second person and at a 7th grade level.  
  
           Numbered the pages of the consent form appropriately. (e.g. Page 1 of 4, Page 2 of 4) 
  
           Indicated that verbal consent will be obtained if written consent is not being obtained. 
  
           Provided a fact sheet for the patient. (A fact sheet should be included for complex, lengthy, or high risk studies.) 
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SECTION II 
PROTOCOL SUMMARY SHEET 
Today's Date: December 14, 2009  
P.I. Name: Steven Hatch Degree: MD  
(PI Must be UMMS Faculty Member) Faculty Title: Instructor 
Department: Center for Infectious Disease and Vaccine Research 
Division Name:  Duration of the Study: 18 months 
Phone # 508-856-4657  Total # of subjects at UMMHC: None 
Beeper/Pager#: 9426  Total # of subjects at off-site locations :  300 
Email Address: steven.hatch@umassmed.edu 
Title of Study: (type right) Maternally Derived Anti-Dengue Antibodies and the Risk of Dengue Hemorrhagic Fever in Infants: a 
Case-Control Study 
 
( Protocol # and version) 
 
 
 
 
 "X" below which sites will participate 
Contact Person Name Steven Hatch Phone # 6-4657 University:  X 
Pager # 9426  Memorial :  
Identify Condition being studied: Dengue Infection (DF/DHF) Marlborough:  
 Shriver Center:  
Source of Funding: Departmental funds Others:  
 
DEVICE INFORMATION                              DRUG INFORMATION 
Please provide IDE# if not approved by FDA   In the table below, list all drugs being used.  If the drug is 
considered investigational by the FDA you must include the 
IND# assigned by the FDA.  Please "X” approved or 
investigational. 
Device Name Approved Investigational IDE# 
    
    
    
 
USE SPACE BELOW FOR COMMENTS OR ADDITIONAL DRUG 
INFORMATION 
 
Drug Name: Approved Inves. IND# 
     
    
    
    
    
    
 
DECRIBE THE RESEARCH BY CHECKING ALL THE ITEMS “YES” OR “NO” 
(**NB: Pregnant Women and Teenage Mothers are eligible though not targeted for study, and so are included in parentheses.) 
Yes No  Yes No  Yes No  
 x On Site at UMMS/UMMMC x  Adults  x Questionnaires (please provide) 
x  Multicenter Study (x)  Pregnant Women  x Filming/video/audio 
x  Cooperating Institutions x  Minors (under 18)  x Marketed drugs 
x  Research Currently Funded (x)  Teenagers ( 12-17)  x Diagnostic Radiation  
 x Financial interest involved  x Prisoners  x Therapeutic Radiation 
 x Funding applied for  x Fetuses / Abortuses  x MRI 
 x UMMMC inpatients  x Randomization  x Ultrasound 
 x UMMMC outpatients  x Placebo  x Radioisotopes 
x  Normal volunteers  x Investigational drugs/device  x Radiation involved? 
x  Other  x Increased hospital costs  x Would receive radiation regardless 
x  Males  x Mental Impairment  x Radiation Safety Approval Needed? 
x  Females  x Data bank  x Biosafety Review Needed? 
 x Phase I Study  x Phase II Study  x Phase III Study 
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 SECTION III 
 PRINCIPAL INVESTIGATOR’S ASSURANCE 
 
As Principal Investigator for this study, I acknowledge and accept my responsibility, as mandated by the UMMS 
Assurance of Compliance for Protecting the rights and welfare of the human subjects taking part in this research 
study. 
 
Assuring that the risks to an individual are outweighed by the potential benefits to him/her or by the 
importance of the knowledge to be gained. 
 
Complying with all the applicable requirements specified by the UMMS Institutional Review Board as a 
condition of IRB approval.   
 
Completing the required education either by reading the Guidelines for the Protection of Human Subjects in 
Research and subsequently answering at least 25 out of 28 questions correctly on the true/false, multiple 
choice, Human Subjects Exam or by completing the required modules for the CITI Course in the Protection 
of Human Research Subjects. 
 
Providing each research subject with a signed copy of the IRB-approved consent form at the time of 
consent. 
 
Retaining the original signed forms in a reasonably secure and confidential area for at least three years after 
termination of the research project. 
 
Obtaining approval from the UMMS IRB of any proposed changes in a previously approved study.   The 
proposed changes will not be implemented before IRB review and approval, unless necessary to eliminate 
apparent immediate hazards to subjects. 
 
Informing the IRB immediately if I become aware of any violations of HHS regulations (45CFR46), FDA 
regulations (21CFR50, 56) or IRB requirements for the protection of human subjects. 
 
Submitting progress reports of approved research as often as, and in the manner prescribed by, the UMMS 
IRB (the frequency of these will be on the basis of risk to subjects, but will be at least annually). 
 
Within 48 hours (in-house events) or five working days (sponsor-reported events) report any unanticipated 
serious adverse experiences, injuries, and other unanticipated problems that involve risks to subjects and 
others, either physical, psychological, or threats to privacy. 
 
Reporting any research subject’s death within five working days, regardless of cause. 
 
Understanding that the failure to comply with all applicable HHS and FDA regulations, IRB 
requirements/policies, and the provisions of the protocol as approved by the IRB may result in suspension 
or termination of my research project.  
 
 The Principal Investigator’s signature must
 
 be obtained before submitting. 
 
Signature of Principal Investigator:         Date: 
                                                                                                         
Type PI name and title:                Steven Hatch, MD                                                                                             
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SECTION IV 
  DEPARTMENTAL / DIVISIONAL APPROVAL 
 
I have reviewed the attached research project for both ethical considerations and technical merit and 
recommend its approval. 
 
I certify that there are adequate resources and facilities to carry out this research, including staff, funding, 
space, recordkeeping capability, and resources to address serious adverse events and possible research-
related injuries. 
 
 
Signature of PI’s Department Chair:                                                                        Date:                           
 
Type Name and title of Chair:                 Francis Ennis, MD                                                                        
 
  
Signature of PI’s Division Chief:                 Date:    
                                                               
Type Name and title of Division Chief:     
 
 
 
Will this research involve faculty or recruit patients from another department besides the department listed above?   
      
 
 
If yes, please complete 
 
MY SIGNATURE BELOW INDICATES THAT I AM AWARE OF AND AGREE TO INVOLVE MY DEPARTMENT IN 
THIS RESEARCH PROJECT 
 
Department Name:  
 
Department Chair Name: 
 
 
Signature of Department Chair:                                                                             Date:  
 
Please “X” boxes below that apply 
 
Faculty from my department will be involved in this research study  
Patients from my department will be involved in this research study  
 
 
 
The section above may be duplicated if there is more than one additional department or faculty member from 
another department that is participating in this study. 
 
 
 
 
Yes  No  
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SECTION V 
 DESCRIPTION OF RESEARCH PROJECT 
 
 
1.  PERSONNEL ENGAGED IN THE RESEARCH STUDY.  List all personnel engaged in the study.  This list must 
agree with that in Section VI (Delegation of roles/responsibilities). 
Steven Hatch, Alan Rothman 
 
2.  GENERAL STATEMENT OF PROBLEM 
 Purpose: Include concise hypothesis to be tested by proposed research. 
 
This study proposes to directly test the hypothesis that antibody-dependent enhancement (ADE) is the 
critical factor in the development of dengue hemorrhagic fever (DHF) in infants. DHF is the life-threatening 
syndrome associated with dengue virus (DENV) infection. The increasing incidence makes an accurate 
model of DHF pathogenesis imperative for vaccine development, clinical management and public health 
strategies. The primary study aim will be to test the hypothesis by comparing the rates of dengue 
seroprevalence of mothers from two groups of infants: infants with DHF and those with symptomatic 
DENV infection but without DHF. Secondary aims include evaluating the relationship between viral load, 
serotype, and disease severity in dengue infected infants; and testing ADE in vitro using the serum from 
the mothers of both groups of dengue infected infants (as a surrogate for ADE activity of pre-illness infant 
sera). 
 
3.   BACKGROUND AND SIGNIFICANCE: 
a. Provide a summary of the facts which led to selection of the problem.  
 
DENV infection is the most common mosquito-borne viral infection in the world today, and has been an 
increasing public health menace over the past few decades. Currently there are an estimated 100-150 
million annual infections, with an annual mortality of >20,000, the overwhelming majority of deaths being 
in infants and children [1]. DENV is a member of the flavivirus family, with four distinct but closely related 
serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Transmitted to humans primarily by Aedes aegypti 
mosquitoes, DENV is found mostly in tropical and subtropical areas worldwide. Classic dengue fever (DF) 
presents as an acute febrile illness characterized by headache, retro-orbital pain, and myalgias. A small 
group of patients go on to develop DHF, which is distinguished from DF principally by a vascular leakage 
phenomenon, leading to hemoconcentration, pleural or peritoneal effusions, and in the most severe 
cases, dengue shock syndrome (DSS). While death is a relatively rare complication, the sheer volume of 
infections worldwide makes DENV the most lethal hemorrhagic fever virus by far—the total number of 
deaths worldwide from Ebola since 1976 is just over 1,000; DENV claims an equal number in less than a 
month. 
 
The protective immune response against DENV remains poorly understood. There are no good animal 
models of human dengue disease [2]; therefore, clinical and epidemiologic studies are necessary to 
answer questions relating to DENV pathophysiology. Further, the development of an effective vaccine 
requires a more comprehensive model of DENV pathophysiology [3]. In particular, an understanding of 
which individuals are at risk for developing DHF is a priority in the coming decade. 
 
Epidemic DHF and DSS emerged in the Philippines and Thailand only 50 years ago. Since then, the virus 
has become hyperendemic in Southeast Asia. Today, it is among the top ten causes of pediatric 
hospitalization in Southeast Asia [4]. By contrast, DENV infection in the Western Hemisphere remained 
relatively low until the 1970s, when DF incidence began to rise, followed by epidemics of DHF and DSS in 
the 1980’s. Today, countries such as Brazil, Venezuela and Colombia are subject to epidemics in 
increasingly rapid succession. The seroprevalence in the West remains less than 100% based on 
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ongoing studies, although hyperendemic circulation is becoming established in some areas [5]. 
 
One of the unique features of dengue is the role of heterologous infection in disease severity. Following 
infection with a given DENV serotype, an individual will develop long-lasting immunity to that serotype 
(homotypic immunity). However, heterotypic immunity to the remaining three serotypes lasts only a few 
months [6]. One key observation in dengue pathogenesis is that heterotypic immunity is a risk factor for 
DHF: the overwhelming majority of DHF cases occur in people who are experiencing secondary infections 
with a different DENV serotype [7]. The major exception to this group is in infants, where “primary DHF” is 
most commonly seen during the period from 6-12 months of age.  
 
One widely accepted theory to account for the occurrence of DHF in these different groups is ADE [8]. 
This model—which has been demonstrated in vitro—proposes that pre-existing heterotypic anti-DENV 
IgG antibodies (Abs) acquired during a previous infection can, under certain conditions, facilitate uptake 
of virus into macrophages and other immune cells via the binding of virus-antibody complexes to Fcγ 
receptors. The consequent increase in receptor-mediated endocytosis leads to higher viral loads, which in 
turn triggers a host inflammatory cascade that leads to DHF. 
 
The sine qua non of the ADE hypothesis is its prediction of DHF during primary DENV infection in infants, 
where maternally derived anti-DENV IgG levels decay over time. Infant immune systems are “primed” in 
utero by passive transfer of DENV-specific Abs from DENV-immune mothers, thus creating a “physiologic 
secondary infection” during primary DENV infection, where waning maternal anti-DENV Abs enhance viral 
uptake, resulting in DHF.  
 
Several epidemiologic studies have shown that the incidence of primary DHF in infants peaks 
approximately between 6 and 8 months [9]. This time frame corresponds with predicted ADE activity, and 
in vitro studies have borne this out [10]. However, other studies have cast doubt on the ADE hypothesis 
[11] [12]. Reflecting these contradictory findings, one investigator recently noted that because 
measurements of ADE rely on in vitro models, its association with clinical outcomes remains controversial 
[13]. They note that “to the best of our knowledge, DHF has not yet been described in an infant born to a 
dengue-naïve mother…further studies of infants with DHF, particularly in regions with low or moderate 
dengue endemicity or where outbreaks occur among previously naïve populations, are needed to 
unequivocally confirm that maternally derived anti-DENV antibody is a critical risk factor for DHF in 
infants.”  
 
We have identified a promising site to study the influence of maternal dengue serostatus on the severity 
of infant DENV infection. Our collaborators are faculty members in the Department of Pediatrics, 
Universidad Surcolombiana (USCO) Hospital. We are currently working with them on a project evaluating 
a novel assay for the detection of dengue viremia. A city of approximately 300,000 people, Neiva is an 
ideal site for studying dengue in infants for two major reasons: it is a small enough city to allow for 
relatively easy follow-up for outpatient study subjects, while it is large enough to have a sufficient number 
of cases of DENV infection. Additionally, USCO is the sole inpatient pediatric hospital not only for the city 
but for the surrounding region; our collaborators and their department care for essentially all cases of DHF 
in Neiva.  
 
b. Please describe the Investigator’s previous work on the problem. 
 
The PI (Hatch) has been working on dengue pathophysiology since the start his research fellowship in 
Infectious Disease in the fall of 2006. He is currently involved in the U01 grant evaluating the novel assay 
for detection of dengue viremia noted above. Dr. Rothman holds that grant and has been involved in the 
study of dengue pathogenesis for over two decades and currently holds several NIH-funded grants 
devoted to the study of dengue. 
                                                           34
  
 
 
c  What are the aspects that justify the use of human subjects, human data, or specimens as part of this research? 
 
Given that dengue infection causes significant morbidity, as well as a negative economic impact, in not 
only Colombia but throughout much of Latin America as well as a small portion of the US, the need to 
establish an accurate model of DHF pathogenesis would be of great value to the field. It is not possible to 
study DHF in animal models because laboratory animals do not develop the salient pathologic features of 
DHF. 
 
d. Attach references as appropriate. 
1. Gubler, D.J., Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic 
problem in the 21st century. Trends Microbiol, 2002. 10(2): p. 100-3. 
2. Yauch, L.E. and S. Shresta, Mouse models of dengue virus infection and disease. Antiviral Res, 
2008. 80(2): p. 87-93. 
3. Thomas, S.J., J. Hombach, and A. Barrett, Scientific consultation on cell mediated immunity (CMI) 
in dengue and dengue vaccine development. Vaccine, 2009. 27(3): p. 355-68. 
4. Kyle, J.L. and E. Harris, Global spread and persistence of dengue. Annu Rev Microbiol, 2008. 62: 
p. 71-92. 
5. Braga, C., et al., Seroprevalence and risk factors for dengue infection in socioeconomically distinct 
areas of Recife, Brazil. Acta Trop, 2009. 
6. Sabin, A.B., Research on dengue during World War II. Am J Trop Med Hyg, 1952. 1(1): p. 30-50. 
7. Sangkawibha, N., et al., Risk factors in dengue shock syndrome: a prospective epidemiologic study 
in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol, 1984. 120(5): p. 653-69. 
8. Halstead, S.B., J.S. Chow, and N.J. Marchette, Immunological enhancement of dengue virus 
replication. Nat New Biol, 1973. 243(122): p. 24-6. 
9. Nguyen, T.H., et al., Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. 
J Infect Dis, 2004. 189(2): p. 221-32. 
10. Kliks, S.C., et al., Antibody-dependent enhancement of dengue virus growth in human monocytes 
as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg, 1989. 40(4): p. 444-51. 
11. Laoprasopwattana, K., et al., Dengue Virus (DV) enhancing antibody activity in preillness plasma 
does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis, 
2005. 192(3): p. 510-9. 
12. Libraty, D.H., et al., A prospective nested case-control study of Dengue in infants: rethinking and 
refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med, 2009. 
6(10): p. e1000171. 
13. Simmons, C.P., et al., Maternal antibody and viral factors in the pathogenesis of dengue virus in 
infants. J Infect Dis, 2007. 196(3): p. 416-24. 
 
 
4.  DETAILED DESCRIPTION OF RESEARCH PLAN (especially as it affects the subject) 
 
a.   Include a schematic representation of what the research will entail (e.g. a table with the number of visits and 
what will happen at each visit or flow diagram of subject’s involvement over time). 
 
We will conduct a case-control study comparing infants and mothers of the following groups: those with 
DHF and those with symptomatic DENV infection but without DHF. All infants will require positive 
laboratory evidence of DENV infection (serology or PCR). Infants with DHF will be defined according to 
the World Health Organization criteria, which include all of the following: thrombocytopenia, a bleeding 
tendency, and plasma leakage. 
 
Infants with symptomatic DENV infection will be screened at an outpatient pediatric clinic affiliated with 
USCO. Plasma leakage in DHF occurs in the period immediately following defervescence. Therefore, 
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children in the symptomatic DENV cohort will be considered eligible for analysis only after they have 
been documented to be free of any DHF manifestations 24 hours after defervescence, although this will 
not affect their initial enrollment status. 
 
To document appropriate clinical follow-up, the study will involve two visits, the second between 48 and 
72 hours after the initial visit. At the initial visit clinical information on both the infant and the mother will be 
collected, and blood will be drawn from both the mother and infant. Mothers of infants at the outpatient 
clinic will be given information about warning signs of severe DENV disease and instructed to return to the 
clinic immediately if the infant develops such symptoms. Hospitalized infants with DHF will be cared for 
according to standard clinical procedures in place at USCO. At the second visit, infants in the outpatient 
clinic will be re-examined and have blood drawn. Infants at the second visit with ongoing fever will be re-
evaluated in a third visit 24-72 hours later, but no further blood will be drawn except as part of standard 
clinical practice. Infants with DHF will be re-evaluated at the second visit, and relevant clinical information 
(chest X-rays, hematocrit and platelet values, amount of IV fluid administered) will be recorded and 
additional blood will be drawn. Mothers will have their blood drawn at the first visit only. 
 
Clinical and demographic data will be collected on the mothers, including age, past or current medical 
history (including specifically a history of Yellow Fever vaccination, previous known dengue infection, 
previous hemorrhagic fever, diabetes, lupus or other autoimmune diseases, asthma, TB and HIV), and 
medications. Similar information will be collected on the infants; additionally, information on the length of 
illness, time from symptom onset to presentation, specific treatments or interventions used, serial CBCs 
and CXRs, serial blood pressure measurements, presence or absence of complications, serial weight and 
height measurements, and mortality will also be collected.  
   
b. Inclusion/Exclusion Criteria - As appropriate, explain what steps will be taken to insure that subjects meet the 
criteria (e.g. healthy, not pregnant, etc). 
 
Inclusion criteria include: 
•Infants aged 12 months or less and their healthy mothers; these infants belong to two groups: 
•Those hospitalized for DHF (diagnosed according to World Health Organization Criteria); and 
•Those sick from infection with dengue but who do not meet the criteria for DHF;  
•Active pregnancy in the mother does not affect inclusion or exclusion criteria. 
 
Exclusion criteria include: 
•For mothers: any febrile illness since the time of delivery of the infant (to exclude an intervening DENV 
infection); 
•Inability or unwillingness to provide informed consent. 
 
c. Discuss the number of experimental and control subjects, and explain the statistical basis for the numbers. 
 
To test the main hypothesis, we will determine whether the DENV seroprevalence is higher in mothers of 
infants with DHF than in mothers of infants without DHF. Based upon estimated seroprevalences of 100% 
among mothers of infants with DHF and 80% among mothers of infants without DHF, with α of .05 and β 
of .2, we calculate that the minimal sample size requirement would be 36 in each arm. We propose to 
recruit in a 1:2 case-control fashion, with a minimum of 50 mother/infant pairs in the DHF group and 100 
mother/infant pairs in the symptomatic DENV group, allowing for withdrawals, loss to follow-up, and 
misdiagnosed patients who do not have dengue (this is far less likely in the DHF arm).  
 
d. Does the study involve randomization?  
  
Yes  No  
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 If yes, please describe process. 
 
e. How long will each subject be enrolled in the study? 
 
We anticipate following patients for two or three days from the time of study inclusion. Mothers 
participating in the study will only be required to give blood at the first visit. Outpatients who remain febrile 
at the second visit will be followed until their fever resolves, although no further blood samples will be 
needed after the second visit. 
 
f. Provide a brief overview of what participation in the study will mean to each participant in terms of what he/she 
will experience.  Describe in order, each procedure, how long each procedure will take and how often each 
procedure will be performed.  Include doses & route of administration of any drugs and whether the procedure or 
drugs would always, sometimes or never be required as part of the subject’s standard of care.  
 
After written consent is provided, the infants will have their blood drawn at each of two visits; mothers will 
have their blood drawn only at the first visit. No medications will be administered as part of the study, 
and all medical therapy, including the use of oral or intravenous fluid supplementation, will be 
administered at the discretion of the attending physician and will follow standard medical care. Basic 
data from the physical examination of the patients, as part of usual clinical practice (such as 
temperature, blood pressure, pulse etc.), in addition to information on the subsequent hospital course of 
those patients who happen to be hospitalized, will also be recorded for the study.  
 
g. Is any aspect of this research study being conducted in the Medical School or a non-UMMMC facility?  If yes, 
please explain. 
 
This study is being conducted at the Department of Pediatrics, Universidad Surcolombiana (USCO), 
Neiva, Colombia. This site represents a place where dengue infection is endemic, and where we have 
established relationships with collaborators interested in various projects on dengue research. 
 
h. Will hospitalization be required as part of this research study? 
 
 
 
If yes, how long will subjects be hospitalized? 
 
i.   Will there be any material inducements or recruitment incentives given to research staff or research subjects as 
part of this research study?  (e.g., direct payments, free hospitalization, care) 
  
   
If yes, explain how much, the pay schedule, or any partial payments that will be given. 
 
As compensation for completing the study, participants will be given gifts of less than US $10 value. 
Transportation reimbursement, in the form of taxi vouchers, bus passes, or subway fare, will be made 
available to all participants who require it. 
 
The committee is exceedingly sensitive to the threat of coercion that can stem from excessive compensation for participation in 
research.  The IRB recommends hourly payments of $20/hr for every hour (or fraction thereof) the subject is involved  in the 
study.  This should include time in the hospital or clinic that is solely for the study, travel time, and time spent recovering from 
a procedure or an anesthetic agent used for a procedure.  Time that the subject is unable to perform his/her routine activities 
of daily living due to study related issues should be included in this time.  (Time required to perform multiple minor tasks 
should be lumped together; that is, filling out a questionnaire that takes 15 minutes on four different days constitutes one hour 
Yes  No  
Yes  No  
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of labor, not four hours.)   If reimbursed, cost of transportation ($0.35/mile), parking and meals should be noted.  A bonus of 
up to $50 may be given for completion of a long term study or for studies that involve low risk but uncomfortable procedures 
(such as endoscopy, multiple blood samples for pharmacokinetic studies, gynecological examinations, etc). 
 
 
 
 
5. DISCLOSURE OF CONFLICT OF INTEREST  
Investigators should disclose any financial arrangement they may have with a company whose product figures 
prominently in their research or financial arrangements they may have with company making a competing product.  
The relationship should also be described in the informed consent documents.  In the case where the only 
relationship is that a company is sponsoring the research study, it is sufficient to prominently identify the sponsor on 
the front page of the consent form and to simply state “NONE” in the consent form under Conflict of Interest. 
 
Is there a conflict of interest?   
   
 
 
6.  RELATIONSHIP TO STANDARD THERAPY. 
Describe the standard therapy that patients would receive if not in the research study.  Explain how this research 
intervention deviates
 
 from or replaces generally accepted standard therapy and justify the deviation. 
For this study, the patients will be evaluated either in an outpatient clinic or on the hospital wards at 
USCO. Their initial evaluation and subsequent care (whether inpatient or outpatient) will not be influenced 
in any way by this study, other than additional blood will be drawn for the research described in this 
proposal (in accordance with amounts considered minimal risk as defined by 45 U.S. Code of Federal 
Regulations (CFR) 46.102). For those study participants who are hospitalized, information on subsequent 
hospital course (including laboratory values described above, chest x-rays, ultrasounds, and amount of IV 
fluid administered) will be abstracted by study personnel. 
 
 
7.  DESCRIBE THE POTENTIAL BENEFITS OF THIS PROJECT. 
a. Include hoped-for benefit to society, to the group of subjects or to individual subjects.   
b. Address the risk/benefit ratio of the study.  If there are no direct subject benefits, this should be stated. 
 
There is no direct benefit to the patients in participating in the study, however the risk/benefit ratio is 
likewise small, given the only risk is by serial phlebotomy. The potential benefit to society lies in the 
possibility that this study may influence the direction of DHF pathophysiologic studies, as well as help 
vaccine researchers consider optimal strategies to measure vaccine effectiveness. 
 
 
 
8.  DESCRIBE THE POTENTIAL RISKS TO SUBJECTS INCLUDE PSYCHOLOGICAL, ECONOMIC, LEGAL OR 
SOCIAL RISKS AS WELL AS PHYSICAL RISKS. 
 
Include the following information: 
 
a. Estimate likelihood of occurrence, severity, and duration.  If generally accepted quantitative estimates are 
available based on previous data, these should be stated.  Otherwise, qualitative estimates such as “rare”, 
“occasionally", or “frequently” may be used.  The committee needs scientific information about drug/device side 
effects so as to best judge the pros and cons of the study.  Do not simply cut and paste the consent form 
“Risk” section into this part of the protocol. 
 
As noted above, phlebotomy is the only procedure of the study that entails risk to the patient, and as such 
Yes  No  
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is in the category of minimal risk. Risks of phlebotomy include lightheadedness (frequent), anemia (rare), 
and venipuncture site infection (rare). 
 
b. Explain what steps will be taken to protect against its occurrence, minimizing the harm, methods for early 
detection of harm, and what procedures will be followed to avoid serious injury (e.g. withdraw from study or dose 
reduction).   
 
Phlebotomy will be performed by trained medical staff at the clinical sites (physicians, nurses, or medical 
technologists). 
 
 
c  Explain whether or not these risks are from a procedure performed with the intent and reasonable prospect of 
yielding direct health related benefit to the subject. 
 
These risks are not from a procedure performed with the reasonable prospect of direct health-related 
benefit to the subject. 
 
d. Do you, as the PI, have equipoise regarding the study?  That is, are you comfortable with the risks in relationship 
to the knowledge gained?  If the study involves randomization, do you believe in the equality of the treatment arms? 
 
We do believe that we have equipoise for the purposes of this study. The risks to the patients are minor, 
and the knowledge gained may help contribute to an understanding of DHF pathogenesis. 
  
 
9.  CONFIDENTIALITY CONSIDERATIONS: EXPLAIN STEPS THAT WILL BE TAKEN TO INSURE THE 
CONFIDENTIALITY OF INFORMATION THAT IS OBTAINED IN THE COURSE OF THIS RESEARCH 
PROJECT.  INCLUDE THE FOLLOWING: 
 
a. How will identifiers be used? Subjects will receive a study ID code identifying the sequence of 
enrollment.  Blood samples collected at follow-up visits will be identified by a different alphanumeric 
specimen ID code.  Data will be recorded on paper case report forms (CRFs) appropriate to the study 
visit.  Blood sample collection data and diagnostic test results will also be recorded on paper CRFs.   
 
b. Where will data be stored? The paper CRFs will be kept at USCO. Copies will be transferred to 
UMass, either by direct transfer of documents or electronically, on a periodic basis for data analysis. 
Analytic files will retain only the unique study ID code attached to each subject in the study. The data will 
be retained on a password protected network drive at CIDVR, or on documents that remain at USCO.  
 
c. Besides the UMMS IRB and their representatives, who will have access to the research data?  
The principal investigator and collaborators. 
 
d. When will the data/specimens be destroyed? The intended use of the archived samples is to further 
work on dengue immunopathogenesis, e.g. Antibody Dependent Enhancement assays, cytokine level 
measurements, plaque reduction neutralization titer (PRNT 50) assays, viral load assessments, etc. The 
well-characterized clinical samples planned to be collected in this study will represent an invaluable 
repository for such studies. The specific assays to be performed will be dependent on the initial data 
analyses from the clinical study. Therefore, we anticipate these research studies to extend for 
approximately three to five years based on our experience with similar clinical studies in Thailand 
performed at CIDVR. 
 Thus, the data and specimens will be retained for at least 5 years. The paper CRFs will be 
destroyed after 5 years; electronic databases (without personal information) and specimens will be 
retained indefinitely. 
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e. In the future, might other use be made of specimens collected as part of the research?  If yes, please 
describe.  A sample repository, when sample banking is possible, will be established, with plasma 
collection occurring for storage and future research investigation. These specimens will be invaluable for 
novel studies not currently anticipated, for example, involving novel assays of DENV-specific antibodies or 
other viral infections relevant to infants and mothers in Colombia. Throughout and after completion of the 
study, proposals for the use of the specimen repository will be solicited from participating investigators as 
well as the scientific community. Proposals will detail the hypotheses to be tested, test(s) to be performed, 
and number of samples required, with appropriate justifications. Proposals will initially be evaluated by the 
Principal Investigator, foreign collaborators, and the UMMS IRB. 
 
 
10.  ECONOMIC CONSIDERATIONS: 
 
a. In the course of this research project, might the subjects experience any additional expenses as a result of 
study participation?  This includes both out-of-pocket costs and expenses that might not be covered by 
medical insurance. 
 
  
 
 
If yes, please explain and justify. 
 
 
b. Please explain potential increase in standard hospital costs if any. 
 
 
 
11.  DESCRIBE THE CHARACTERISTICS OF THE SUBJECT POPULATION. 
 
a. The subject population includes: 
 
  ADULTS        x   CHILDREN      X      
 
b. Is the subject population restricted in respect to any of the following characteristics? 
   
  
Please “x” those that apply Yes No 
Age Range x  
Health Status  x 
Gender (x)  
Racial/Ethnic composition  x 
 
 
If you responded YES to any of the above, include a clear rationale for this restriction. 
See above—the study is targeting mothers of infants suffering from either symptomatic dengue infection 
or from DHF, and the infants themselves. The phenomenon of DHF outlined in #3a can only be studied in 
this group. Infants can be of either sex, but because of maternal passage of antibodies to fetuses, 
mothers are the only eligible parents for this study. 
 
 
12.  WILL THE STUDY POPULATION SPECIFICALLY INCLUDE A POPULATION OF SUBJECTS 
CONSIDERED “VULNERABLE”?  VULNERABLE POPULATIONS ARE CHILDREN, MENTALLY IMPAIRED, 
PREGNANT WOMEN, PRISONERS, OR FETUSES. 
 
   
Yes  No  
Yes  No  
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If yes, please explain. 
Per above, the study populations include both infants and potentially pregnant women (although given the 
targeted age of infants we do not anticipate many mothers to be pregnant). While these are both 
vulnerable populations, this study poses only minimal risk to participants and is of short duration. 
 
 
13.  WHAT IS THE SOURCE OF THE SUBJECT POPULATION? 
The study population consists of infants with DHF or those suspected of having symptomatic dengue 
infection, and the mothers of both groups of infants, living in the catchment area of the USCO hospital. 
 
 
14.  EXPLAIN ANY STEPS TAKEN TO INSURE THAT THE SUBJECT POPULATION IS REPRESENTATIVE. 
Not applicable. 
 
 
 
15.  HOW AND WHERE WILL SUBJECTS BE RECRUITED FOR THE STUDY?  CONSULT THE IRB 
GUIDELINES FOR THE RESTRICTIONS ON RECRUITMENT OF EMPLOYEES, STUDENTS, AND 
INPATIENTS. ATTACH COPIES OF ALL RECRUITMENT MATERIALS TO BE USED AS PART OF THIS 
RESEARCH STUDY.  THESE MATERIALS MUST BE APPROVED BY THE IRB BEFORE BEING USED. 
Recruitment guidance can be found on our website under HSC Forms. 
We will recruit study participants among patients presenting to either with suspected DHF (at the USCO 
hospital wards) or suspected symptomatic dengue infection (at the outpatient clinic). The project staff 
(consisting of physicians and nurses) will identify patients who meet the inclusion criteria for the study. 
Such patients will then be approached by project staff. They will explain the study protocol and consent 
forms (in Spanish) in detail. Any questions regarding the study will be addressed, and written informed 
consent will be taken at the day of enrollment. Mothers will be excluded if they are unable or unwilling to 
provide consent. Participants may leave the study at any time without penalty. 
 
 
16. WILL PROTECTED HEALTH INFORMATION (PHI) BE USED AS PART OF THIS RESEARCH STUDY?  
PLEASE VISIT OUR WEBSITE FOR MORE INFORMATION ABOUT PHI OR THE HEALTH INSURANCE 
PORTABILITY AND ACCOUNTABILITY ACT (HIPAA). 
  
 
  
 If yes, please answer the following questions. 
 
a. How and where will the PHI be accessed (i.e. meditech, database,medical records, another site)? 
 
 
 
 
b. W   j       j      y  
 
 
 
 
Yes  No  
No PHI will be sent to UMMS; only coded information will be sent to UMMS, with 
the link to the code kept at USCO. 
 
Yes—infants considered for inclusion into the DHF arm will be identified by 
physicians or nurses after a review of their medical record. We emphasize that 
this information will be obtained by staff actively engaged in the care of the infants 
and therefore the PHI is not being accessed outside of the normal course of 
events. The infants in the symptomatic dengue infection arm will not have their 
PHI accessed before study enrollment. Mothers participating in the study will not 
have any PHI accessed beyond that given at the time of study enrollment.  
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c. Please list the PHI to be used as part of this research study (i.e. name, DOB, medical record #). 
 
 
 
 
 
 
 
 
 
17.  METHOD FOR OBTAINING INFORMED CONSENT 
 
a. Are you requesting a waiver of the requirement for obtaining consent? 
 
 
   
 
If yes, please justify
 
 the request in the box below.  Consent may be waived if research is minimal risk; the waiver 
does not adversely affect the subject and the research could not practically be carried out without the waiver.  
Your justification must address these issues. Specific regulations can be found at 45 CFR 46.117 (c) (1) (2) and 21 
CFR 56.109 (c) (1) 
 
 
 
 
 
 
 
 
Do not complete the following questions if you are requesting a waiver of informed consent. 
18.  WILL VERBAL CONSENT BE OBTAINED? 
 
   
If yes, will an unsigned “fact sheet” be given to subjects before verbal consent is obtained? 
 
 
   
 If yes, please provide a copy of the “fact sheet”. 
 
19.  WILL A SIGNED CONSENT FORM BE REQUIRED? 
 
  
 
 
20. AS A GROUP, ARE THESE SUBJECTS EXPECTED TO BE COMPETENT TO GIVE CONSENT FOR 
THEMSELVES? 
 
 
 
   
 If no, please explain why and how consent will be obtained. Mothers will consent for themselves and for their 
infants. 
 
21. EXPLAIN THE CIRCUMSTANCES UNDER WHICH CONSENT WILL BE OBTAINED.  HOW WILL YOU 
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Yes  No  
DOB; age; past or current medical history (including specifically a history of Yellow 
Fever vaccination, TB, previous dengue infection, previous hemorrhagic fever, 
diabetes, lupus or other autoimmune diseases, asthma, and HIV); medications; and 
for infants in the DHF arm (or those infants in the symptomatic dengue infection arm 
that require hospitalization) data collected during the course of illness or 
hospitalization (including specifically treatments or interventions, serial CBCs and 
CXRs). 
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INSURE THAT POTENTIAL SUBJECTS HAVE ADEQUATE TIME TO CONSIDER THEIR OPTIONS, AND 
THAT POSSIBLE COERCION IS MINIMAL? 
 
After proper identification of appropriate subjects for the study, potential participants will be 
approached by study staff (all of whom have taken NIH-mandated courses in ethics of human subjects 
research), explained the purpose of the study in non-technical language and provided with consent forms. 
All questions will be addressed in due course without respect to their number or length. Research staff will 
make clear at the initial encounter that no aspect of the participants’ subsequent health care will be 
affected by their decision to participate in the study, and moreover that no penalty will ensue should they 
elect to withdraw from the study. Participants will be offered assistance with transportation costs 
associated with the study and told that they will be given a “gift” of small value as part of minimal 
compensation for their participation (as noted above); however there are no financial incentives that are 
sufficient to induce participation in those who would otherwise be reluctant to do so. 
 Consent and assent forms will be in Spanish. The English translations of these forms are in the 
appendix. 
 
22.  IF THE SUBJECT POPULATION INCLUDES MINORS, AND SIGNED CONSENT WILL BE OBTAINED, 
WILL AN ASSENT FORM BE USED AS PART OF THE CONSENTING PROCESS?  CONSULT IRB 
GUIDELINES FOR INFORMATION ABOUT CHILDREN IN RESEARCH STUDIES. 
 
 
  
 
 
NOTE: In general, it is expected that minors from age 8 to 15 will read and sign an assent form.   
Older adolescents (16 and 17) will usually read and sign the same consent form as the parents 
signed.  The assent form template is available on our website. 
 
 
 
23.  IF YES, PLEASE EXPLAIN WHO WILL APPROACH THE MINORS AND HOW AND WHERE THE  
ASSENTING PROCUDURE WILL TAKE PLACE.  
 
 
 
 
 
 
 
 
Yes  No Minors enrolled  Verbal consent requested  
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SECTION VI 
CERTIFICATION OF APPROVAL 
PI Name: 
DELEGATION OF ROLES/RESPONSIBILITIES*:  Checklist/Signature List 
 
Please type 
Name and 
Credentials 
 
Role* 
 
Signature 
 
Department/Campus 
Delegation of responsibilities: 
Please use key** in box below to 
summarize your study activities and 
place an “x” in the appropriate column 
A B C D E F G H I J 
 
 
Steven 
Hatch, MD 
 
PI 
  
CIDVR/University 
      
X 
  
X 
 
X 
 
X 
 
Alan 
Rothman, 
MD 
 
1  CIDVR/University      X  X X  
 
 
             
 
 
             
 
 
             
 
 
             
 
 
             
 
 
             
*Roles: (choose appropriate # below) 
1. Sub or Co-Investigator  2. Study Nurse 
Coordinator 
3. Study Coordinator 4. Other: 
 
**Delegation of Responsibility Codes: (choose all that apply) 
A. Consent Subjects F.  Maintain Regulatory Documents 
B. Take Medical History G. CRF Completion and Query Resolution 
C. Conduct Physical Exam H. SAE/AE Monitoring/Reporting 
D.  Phlebotomy I.   IRB Communications and Continuing Review 
E. Monitor Vital Signs/Nursing Assessment J. Other (explain): obtain and ensure accuracy of data; 
perform lab analysis, write abstracts and manuscripts 
 
Although the Principal Investigator is ultimately responsible for every element of study activity, this form serves to 
clarify to whom the PI has delegated specific study activities and responsibilities. 
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APPENDIX #3: Maximum Allowable  
Total Blood Draw Volumes (Clinical + Research) 
 
Body Wt 
(Kg) 
Body Wt 
(lbs) 
Total blood 
volume (mL) 
 
Maximum allowable 
volume (mL) in       
one blood draw 
( = 2.5% of total 
blood volume) 
Total volume 
(clinical + 
research)     
maximum volume  
(mL) drawn in a 
30-day 
Minimum 
Hgb 
required 
at time 
of blood 
draw period 
Minimum Hgb 
required at time of 
blood draw if 
subject has 
respiratory/CV 
compromise 
1 2.2 100 2.5 5 7.0 9.0 -10.0 
2 4.4 200 5 10 7.0 9.0-10.0 
3 6.3 240 6 12 7.0 9.0-10.0 
4 8.8 320 8 16 7.0 9.0-10.0 
5 11 400 10 20 7.0 9.0-10.0 
6 13.2 480 12 24 7.0 9.0-10.0 
7 15.4 560 14 28 7.0 9.0-10.0 
8 17.6 640 16 32 7.0 9.0-10.0 
9 19.8 720 18 36 7.0 9.0-10.0 
10 22 800 20 40 7.0 9.0-10.0 
11-15 24-33 880-1200 22-30 44-60 7.0 9.0-10.0 
16-20 35-44 1280-1600 32-40 64-80 7.0 9.0-10.0 
21-25 46-55 1680-2000 42-50 64-100 7.0 9.0-10.0 
26-30 57-66 2080-2400 52-60 104-120 7.0 9.0-10.0 
31-35 68-77 2480-2800 62-70 124-140 7.0 9.0-10.0 
36-40 79-88 2880-3200 72-80 144-160 7.0 9.0-10.0 
41-45 90-99 3280-3600 82-90 164-180 7.0 9.0-10.0 
46-50 101-110 3680-4000 92-100 184-200 7.0 9.0-10.0 
51-55 112-121 4080-4400 102-110 204-220 7.0 9.0-10.0 
56-60 123-132 4480-4800 112-120 224-240 7.0 9.0-10.0 
61-65 134-143 4880-5200 122-130 244-260 7.0 9.0-10.0 
68-70 145-154 5280-5600 132-140 264-280 7.0 9.0-10.0 
71-75 156-185 5680-6000 142-150 284-300 7.0 9.0-10.0 
76-80 167-176 6080-6400 152-160 304-360 7.0 9.0-10.0 
81-85 178-187 6480-6800 162-170 324-340 7.0 9.0-10.0 
86-90 189-198 6880-7200 172-180 344-360 7.0 9.0-10.0 
91-95 200-209 7280-7600 182-190 364-380 7.0 9.0-10.0 
96-100 211-220 7680-8000 192-200 384-400 7.0 9.0-10.0 
 
 
 
Based on blood volume of: 
kg mL/kg  
1-2 100 Pre-term infant 
> 2 80 Term infant - adult 
 
 
This information is similar to that used by the Committee on Clinical Investigations, Children’s 
Hospital in Los Angeles, CA; Baylor College of Medicine, Dallas, TX; and Cincinnati Children’s 
Hospital Institutional Review Board, OH. These charts were adapted by:  Rhona Jack, Ph.D. 
Children’s Hospital and Regional Medical Center Laboratory, Seattle, WA in August 2001. 
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 APPENDIX #4: 
 
INFORMED CONSENT (ENGLISH TRANSLATION) 
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
TITLE: Maternally Derived Anti-Dengue Antibodies and the Risk of Dengue 
Hemorrhagic Fever in Infants: a Case-Control Study 
 
PRINCIPAL INVESTIGATORS: Doris Salgado and Jairo Rodriguez DATE: __________ 
 
RESEARCH SUBJECT'S NAME: ____________________________ 
 
You and your child are invited to participate in a research study so that researchers may learn 
more about how infants become sick from dengue infection. This form will tell you why the study 
is being done and what will be done if you decide to take part in the study. 
 
The objective of this study is to learn how previous infection with dengue virus in a mother can 
affect how ill the child becomes when he or she gets infected with dengue as an infant. The 
dengue virus is carried by mosquitoes and is very common in Colombia. Most people who get 
dengue become sick with fever, headache, weakness and muscle aches (dengue fever). 
However, some people become sicker, developing dengue hemorrhagic fever with 
complications such as bleeding or shock (low blood pressure). Your child is suspected to be 
sick from dengue infection, although certain tests will need to be done in order to confirm this. 
Purpose of research 
 
Doctors at Universidad Surcolombiana (USCO) are working with scientists from the University of 
Massachusetts Medical School in the United States to study the influence of prior infections in 
mothers on infants who become infected with the dengue virus. Researchers want to compare 
mothers of infants who have dengue hemorrhagic fever with mothers of infants who have 
dengue fever. The researchers will perform special blood tests on mothers and infants of both 
groups. 
 
It is important for you to know that: 
Your rights 
1) YOUR PARTICIPATION IS ENTIRELY VOLUNTARY. 
2) YOU MAY DECIDE NOT TO TAKE PART OR DECIDE TO QUIT THE STUDY AT ANY 
TIME, WITHOUT ANY PENALTY. 
3) YOU WILL BE TOLD ABOUT ANY NEW INFORMATION OR CHANGES IN THE STUDY 
THAT MIGHT AFFECT YOUR PARTICIPATION. 
 
The first thing that will be done is to determine if you qualify for this study. You have been 
approached because your child is likely to be infected with the dengue virus; there is no 
reason to believe that you are ill from dengue infection at this time. The doctor or nurse will 
collect information and take a blood sample from you, and a much smaller sample from your 
child today. No further blood samples will be taken from you, although the doctor or nurse will 
collect a second sample on your child. If you have brought your child to the clinic, you will be 
asked to return to the clinic two days from now. If your child is in the hospital, the doctor or 
nurse will collect the sample while your child is still in the hospital two days from now.  
Study procedures 
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 You are being asked to do the following:  
-You will see the doctor or nurse conducting this study. This visit should last about 15 minutes.  
-You will be asked some questions about your health. 
-You will not be examined by the doctor or nurse in the clinic. 
-A blood sample (about 12 ml, or the amount of blood in a vial a little larger than the size of your 
3rd finger) will be drawn from your arm with a needle.  
-A much smaller sample (about 2 ml) will be drawn from your child today, and the same amount 
will be drawn in two days.  
 
All of your blood is being used strictly for research. Your child’s blood is being used mostly for 
the research study. If your child were not in the research study, he or she might have some of 
these tests done anyway. 
 
If the doctor thinks that your child needs additional medical care, you may be referred to the 
hospital. If your child is admitted to the hospital, members of the health care team conducting 
the study will visit you in the hospital during the scheduled visit days to obtain a blood sample. 
The results of these studies will be added to your hospital record.  
 
Blood drawing can cause some symptoms. Some people may feel lightheaded or even faint. 
Blood drawing may also cause pain and bruising. The amount of blood collected in this study is 
very unlikely to cause anemia (low red blood count). 
Risks of the experimental procedures 
 
You might benefit in one of the following ways: 
Benefits 
1) The costs of the medical tests required for this research study will be paid by the researchers. 
2) The information collected in this study may benefit you or others in the future by helping 
doctors find the best ways to treat patients with dengue, and also by helping doctors design an 
effective vaccine against dengue. 
3) However, it is likely that neither you nor your child will obtain any benefit from 
participating in this project. 
 
There will be no additional costs to you for participating in this study. Clinic visits and laboratory 
tests that are required for this research study will be free of charge. 
Costs 
 
Compensation
You will receive financial compensation each day you come into the clinic to defray the 
cost of traveling to the clinic. When you complete the study, you will also receive a gift of 
less than US $10 (or the local currency equivalent). 
. 
 
If you choose not to participate, your child will still receive treatment for your illness and undergo 
the standard blood tests and other tests that you need. 
Alternatives 
 
 
Yours and your child’s research records will be kept confidential. In all study records you and 
your child will be identified by a code number and your names will be known only to the 
researchers. Your names will not be used in any reports or publications of this study. 
Confidentiality 
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 You may withdraw from this study at any time. You may also be withdrawn from this research 
study by the study physician if he/she feels that it is not in you or your child’s interest to continue 
to participate. 
Withdrawal from the study 
 
The quality of care you receive at this hospital or clinic will NOT be affected in any way if 
you decide not to participate or if you withdraw from the study.  
 
If you or your child are injured or have any harmful effects as a direct result of you or your 
child’s participation in this research, treatment will be made available to you or your child. Only 
necessary medical treatment will be offered; neither you nor your child will receive any 
additional compensation. 
Research injury/compensation 
 
The blood samples that will be taken from you will be used to test for past dengue 
infection. Samples will be stored at USCO or at the University of Massachusetts. As part of this 
study, the investigators plan to collect and store extra samples. These samples may be used for 
future research to learn more about dengue and other diseases. Samples may also be shared 
with investigators at other institutions. In some research, your samples may enable researchers 
to develop medical tests or treatments that have commercial value. You will not receive any 
money that may result from any such commercial tests or treatments. Genetic research may be 
performed on your samples to study more about the nature of dengue disease; however, no 
genetic information obtained from this research will be placed in your child’s medical records. 
For any such studies, the samples will be identified only by codes so that you or your child’s 
name cannot be easily identified. 
Use of samples 
 
Any additional research studies using your samples will be reviewed by the investigators' 
Institutional Review Board, a committee that oversees medical research to protect the rights and 
welfare of the volunteers. 
 
You can change your mind at any time about allowing your identifiable samples to be used for 
future research. If you do, contact the investigators and let them know. Then your samples will 
no longer be made available for research. 
 
Researchers may want to know more about you in the future. If you agree to be re-contacted, 
you may still change your mind about providing information in the future. 
 
(Please check below to indicate whether or not you may be contacted in the future.) 
 
__ I may be re-contacted for information. 
__ I may not be re-contacted for information. 
 
Subject initials __________        Date ________ 
 
 
 
Please feel free to ask any questions you may have about the study or about your rights as a 
research subject.  If other questions occur to you later, you may ask: 
Questions 
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 At USCO—Dr. Doris Salgado or Dr. Jairo Rodriguez, telephone (telephone number inserted 
here). 
If at any time during or after the study, you would like to discuss the study or your research 
rights with someone who is not associated with the research study, you may contact (additional 
contact information inserted here). 
 
The purpose and procedures of this research project have been explained to me and I 
understand them. I have been told about all of the predictable discomfort, risks, and benefits 
that might result, and I understand them. I have been told that unforeseen events may occur. I 
agree to participate as a subject in this research project. I understand that I may end my 
participation at any time. 
 
Subject's signature: _______________________________    DATE: _______________ 
 
NAME:________________________________________ 
 
 
Witness signature: _________________________________    DATE: ______________ 
 
NAME:________________________________________ 
 
 
INVESTIGATOR'S DECLARATION 
 
I have explained to the above-named subject the nature and purpose of the procedures 
described above and the foreseeable risks, discomforts, and benefits that may result.  I have 
asked the subject if any questions have arisen regarding the procedures and have answered 
these questions to the best of my ability.  I have considered and rejected alternative procedures 
for answering this research question. 
 
_____________________________________________DATE:_____________ 
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 APPENDIX #5: Informed Consent, Spanish Translation 
 
CONSENTIMIENTO INFORMADO 
 
CONSENTIMIENTO PARA PARTICIPAR EN UN ESTUDIO DE INVESTIGACIÓN 
 
TÍTULO: Anticuerpos contra el dengue derivados de la madre y riesgo de fiebre del 
dengue hemorrágico en bebés: Estudio de casos y controles 
 
INVESTIGADORES PRINCIPALES: Doris Salgado y Jairo Rodriguez FECHA: __________ 
 
NOMBRE DEL SUJETO DE INVESTIGACIÓN: ____________________________ 
 
Estamos invitando a usted y su niño a participar en un estudio de investigación para que los 
investigadores puedan aprender más sobre la forma en que los bebés se enferman por la 
infección por dengue. Este formulario le explica por qué estamos llevando a cabo el estudio y lo 
que se hará si usted decide participar. 
 
El objetivo de este estudio es averiguar de qué forma una infección anterior con un virus de 
dengue en la madre puede afectar la severidad de la enfermedad en el niño cuando éste se 
infecta con dengue siendo bebé. En Colombia, los virus de dengue son portados por los 
mosquitos y son muy comunes. La mayoría de las personas infectadas por el dengue se 
enferman con fiebre, dolores de cabeza, debilidad y dolores musculares (fiebre del dengue). 
Sin embargo, algunas personas se enferman más y desarrollan fiebre del dengue hemorrágico, 
con complicaciones como sangrado o shock (presión arterial baja). Se sospecha que su niño 
está enfermo por una infección con dengue, aunque para confirmarlo será necesario hacer 
ciertas pruebas. 
Propósito de la investigación 
 
Los médicos de la Universidad Surcolombiana (USCO) están colaborando con científicos de 
University of Massachusetts Medical School de Estados Unidos para estudiar la influencia de 
infecciones previas en las madres, en bebés que contraen una infección con virus de dengue. 
Los investigadores quieren comparar a madres de bebés que tienen fiebre del dengue 
hemorrágico con madres de bebés que tienen fiebre del dengue. Para ello, les harán análisis 
de sangre especiales a madres y niños de ambos grupos. 
 
Es importante que usted sepa que: 
Sus derechos 
1) SU PARTICIPACIÓN ES TOTALMENTE VOLUNTARIA. 
2) USTED PUEDE DECIDIR QUE NO PARTICIPARÁ O QUE SE RETIRARÁ DEL ESTUDIO 
EN CUALQUIER MOMENTO, SIN NINGUNA PENALIDAD. 
3) LA MANTENDREMOS AL TANTO DE CUALQUIER INFORMACIÓN NUEVA O CAMBIO EN 
EL ESTUDIO QUE PUEDA AFECTAR SU PARTICIPACIÓN. 
 
Lo primero que se hará es determinar si usted reúne los requisitos para participar en este 
estudio. A usted la han invitado a participar porque es probable que su niño esté infectado con 
un virus de dengue; en este momento no hay motivos para creer que usted esté enferma 
por infección con un virus de dengue. Hoy, el médico o la enfermera obtendrán información 
y le extraerán una muestra de sangre a usted y otra muestra de sangre mucho más pequeña a 
su niño. A usted no le extraerán ninguna otra muestra de sangre, pero a su niño le extraerán 
Procedimientos del estudio 
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 una segunda muestra. Si usted ha traído a su niño a la clínica, le pedirán que vuelva a la clínica 
en dos días. Si su niño está hospitalizado, el médico o la enfermera obtendrán la muestra en 
dos días mientras su niño esté todavía en el hospital.  
 
A usted se le pide que haga lo siguiente:  
- Ver al médico o la enfermera que lleva a cabo este estudio. Esta visita debería durar 
aproximadamente 15 minutos.  
- Contestar algunas preguntas sobre su salud. 
- El médico o la enfermera no la examinará en la clínica. 
- Con una aguja, le extraerán una muestra de sangre de aproximadamente 12 mililitros (menos 
de tres cucharaditas) de un brazo.  
- A su niño se le extraerá una muestra de sangre mucho más pequeña hoy (aproximadamente 
2 mililitros, menos de media cucharadita) y la misma cantidad en dos días.  
 
Toda su sangre se usará exclusivamente para la investigación. La sangre de su niño se usará 
en su mayor parte para el estudio de investigación. Si su niño no estuviera en el estudio de 
investigación, posiblemente le harían algunas de estas pruebas de todos modos. 
 
Si el médico opina que su niño necesita atención médica adicional, tal vez los envíen al 
hospital. Si su niño es hospitalizado, los miembros del equipo de atención médica que realiza el 
estudio los visitarán en el hospital durante los días planificados para obtener la muestra de 
sangre. Los resultados de estos estudios se incorporarán a su historial médico.  
 
La extracción de sangre puede causar algunos síntomas. Algunas personas pueden sentir 
mareos o desmayarse. La extracción de sangre también puede causar dolor y hacer que se 
formen moretones. Es muy improbable que la cantidad de sangre extraída en este estudio 
cause anemia (un recuento bajo de glóbulos rojos). 
Riesgos de los procedimientos experimentales 
 
Usted podría beneficiarse de una de las siguientes maneras: 
Beneficios 
1) Los costos de las pruebas médicas necesarias para este estudio de investigación serán 
pagados por los investigadores. 
2) La información obtenida mediante este estudio tal vez beneficie a ustedes o a otros en el 
futuro al ayudar a los médicos a encontrar mejores maneras de tratar a los pacientes con 
dengue y a elaborar una vacuna eficaz contra esta enfermedad. 
3) Sin embargo, es probable que ni usted ni su niño obtengan ningún beneficio por 
participar en este proyecto. 
 
La participación en este estudio no implicará ningún costo adicional para usted. Las visitas a la 
clínica y las pruebas de laboratorio requeridas para este estudio de investigación serán 
gratuitas. 
Costos 
 
Compensación
Usted recibirá compensación económica cada día que venga a la clínica para cubrir sus 
gastos de viaje a la clínica. Cuando complete el estudio, también recibirá un regalo de 
menos que $10 dólares estadounidenses (o el equivalente en moneda local). 
. 
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 Su niño recibirá tratamiento para su enfermedad y se le harán los análisis de sangre estándar y 
otras pruebas que necesite aun si usted decide no participar en el estudio. 
Alternativas 
 
 
Los archivos de investigación de usted y de su niño se mantendrán confidenciales. En todos los 
archivos del estudio, usted y su niño serán identificados mediante un código numérico y los 
únicos que sabrán sus nombres serán los investigadores. Los nombres de usted y su niño no 
se usarán en ningún informe o publicación que surja de este estudio. 
Confidencialidad 
 
Usted puede retirarse del estudio en cualquier momento. Además, el médico investigador 
también puede retirarlos de este estudio de investigación si opina que seguir participando no es 
lo más conveniente para su niño. 
Retirarse del estudio 
 
La calidad de la atención médica que usted reciba en este hospital o clínica NO se verá 
afectada de ninguna manera si usted decide no participar o se retira del estudio.  
 
Si usted o su niño se lesionan o sufren algún efecto perjudicial como resultado directo de su 
participación en esta investigación, se les ofrecerá tratamiento. Solamente se les ofrecerá el 
tratamiento médico necesario; ni usted ni su niño recibirán ninguna compensación adicional. 
Compensación por lesiones relacionadas con la investigación 
 
Las muestras de sangre extraídas se analizarán para detectar infección previa por 
dengue. Las muestras se almacenarán en USCO o en la Universidad de Massachusetts 
(University of Massachusetts). Como parte de este estudio, los investigadores planean obtener 
y almacenar muestras adicionales. Estas muestras pueden usarse para investigaciones futuras 
con el fin de aprender más sobre el dengue y otras enfermedades. Las muestras también 
pueden compartirse con investigadores de otras instituciones. En algunos estudios de 
investigación, sus muestras podrían permitir que los investigadores desarrollen pruebas o 
tratamientos médicos que tienen valor comercial. Usted no recibirá ningún dinero que surja a 
raíz de cualquiera de estas pruebas o tratamientos comerciales. Es posible que se haga 
investigación genética con sus muestras para estudiar más a fondo la naturaleza de la 
enfermedad de dengue; sin embargo, en los historiales médicos de su niño no se colocará 
ninguna información genética obtenida a través de esta investigación. Para cualquiera de estos 
estudios, las muestras se identificarán solamente por códigos para que el nombre de usted y su 
niño no puedan ser identificados fácilmente. 
Uso de las muestras 
 
Cualquier estudio de investigación adicional en el que se use sus muestras será inspeccionado 
por la Junta de Revisión Institucional de los investigadores. Una Junta de Revisión Institucional 
es un comité que supervisa las investigaciones médicas para proteger los derechos y el 
bienestar de los participantes voluntarios. 
 
Usted puede cambiar de parecer en cualquier momento con respecto a su permiso para que 
sus muestras identificables se usen en investigaciones futuras. Si así lo hace, comuníquese 
con los investigadores y hágaselo saber. A partir de ese momento, sus muestras ya no estarán 
disponibles para la investigación. 
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 Los investigadores tal vez quieran saber más sobre usted en el futuro. Aun si acepta que 
vuelvan a comunicarse con usted, puede cambiar de opinión con respecto a ofrecer 
información en el futuro. 
 
(Por favor, marque a continuación para indicar si acepta o no que se vuelvan a comunicar con 
usted en el futuro). 
 
__ Acepto que vuelvan a comunicarse conmigo para pedir más información. 
__ No acepto que vuelvan a comunicarse conmigo para pedir más información. 
 
Iniciales del sujeto __________        Fecha ________ 
 
 
Por favor siéntase en libertad de hacer cualquier pregunta que tenga sobre el estudio o sobre 
sus derechos como un sujeto de investigación. Si se le ocurren otras preguntas más adelante, 
puede dirigirlas a: 
Preguntas 
En USCO, Dra. Doris Salgado o Dr. Jairo Rodriguez, teléfono: (insertar número de teléfono 
aquí). 
Si en cualquier momento, durante o después del estudio, usted desea hablar sobre el mismo o 
sobre sus derechos como participante en una investigación con alguien no relacionado con 
este estudio, puede ponerse en contacto con (insertar información adicional de contacto 
aquí). 
 
Me han explicado el propósito y los procedimientos de este proyecto de investigación y los 
comprendo. Me han informado de todas las molestias, riesgos y beneficios previsibles que 
podrían ocurrir, y los comprendo. Me han informado que pueden ocurrir acontecimientos 
imprevistos. Acepto participar como sujeto en este proyecto de investigación. Entiendo que 
puedo dejar de participar en cualquier momento. 
 
Nombre del sujeto: _______________________________    FECHA: _______________ 
 
NOMBRE: ________________________________________ 
 
 
Firma del testigo: _________________________________    FECHA: ______________ 
 
NOMBRE: ________________________________________ 
 
 
DECLARACIÓN DEL INVESTIGADOR 
 
He explicado al sujeto mencionado anteriormente la naturaleza y el propósito de los 
procedimientos descritos más arriba y los riesgos, molestias y beneficios previsibles que 
podrían ocurrir. Le he preguntado al sujeto si tenía preguntas con respecto a los 
procedimientos y he contestado estas preguntas a mi leal saber y entender. He considerado y 
rechazado procedimientos alternativos para contestar esta pregunta de investigación. 
 
_____________________________________________ FECHA: _____________ 
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